WO1993016728A1 - Improved vaccin against brucella abortus - Google Patents

Improved vaccin against brucella abortus Download PDF

Info

Publication number
WO1993016728A1
WO1993016728A1 PCT/US1993/001681 US9301681W WO9316728A1 WO 1993016728 A1 WO1993016728 A1 WO 1993016728A1 US 9301681 W US9301681 W US 9301681W WO 9316728 A1 WO9316728 A1 WO 9316728A1
Authority
WO
WIPO (PCT)
Prior art keywords
abortus
vaccine
mutant
transposon mutant
polysaccharide antigen
Prior art date
Application number
PCT/US1993/001681
Other languages
French (fr)
Inventor
Leslie G. Adams
Richard P. Crawford
Donald S. Davis
Thomas A. Ficht
Roger Smith, Iii
Blair A. Sowa
Joe W. Templeton
John D. Williams
Albert M. Wu
Original Assignee
The Texas A & M University System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Texas A & M University System filed Critical The Texas A & M University System
Priority to EP93907031A priority Critical patent/EP0627935A4/en
Priority to BR9305970A priority patent/BR9305970A/en
Publication of WO1993016728A1 publication Critical patent/WO1993016728A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/098—Brucella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • the present invention relates to an improved vaccine against Brucella abortus.
  • the invention is a novel vaccine in which specific antigens of Brucella abortus induce an immunological response which provides protective immunity yet permits differentiation between field strain infected and vaccinated cattle.
  • This novel vaccine is made from either an O polysaccharide antigen deficient transposon mutant of B. abortus or from cell envelopes isolated from such a transposon mutant.
  • Brucella abortus are gram-negative coccobacilli that affect the reproductive system of cattle.
  • the organism is a facultative intracellular parasite capable of causing spontaneous abortion, reduced milk production, delayed conception in cows and sterility in bulls. Brucellosis in humans and laboratory animals does not ordinarily involve the reproductive system.
  • LPS consists of an hydrophobic lipid A region, the oligosaccharide core and the O-polysaccharide side chain which gives the cell surface its hydrophilic character.
  • Native hapten which has recently been identified as the O-polysaccharide (Moreno, E., H. Mayer, and I. Moriyon. 1987. Characterization of a native polysaccharide hapten from Brucella melitensis. Infect. Immun.
  • polysaccharide B is a complex mixture of low molecular weight glucans (Bundle, D.R., J.W. Chenwonogrodzky, and M.B. Perry. 1988. Characterization of brucella polysaccharide B. Infect. Immun. 56:1101-1106).
  • the O-polysaccharide side chain of the LPS is the most antigenic and has been shown to elicit a protective immune response in the mouse model (Montaraz, J.A.,
  • the vaccines are generally prepared using either live or killed strains of Brucella. The most common of these is strain 19. The use of these vaccines has several disadvantages.
  • One disadvantage is that currently there is no consistently effective means for distinguishing strain 19 vaccinated cattle from those infected by pathogenic strains of Brucella abortus. Both the vaccine and the pathogenic strain cause the production of cross-reacting antibodies which serve as the basis for current serological tests for brucellosis.
  • McEwen McEwen, A.D. The virulence of B. abortus for laboratory animals and pregnant cattle. Vet. Rec. 1940; 52:97-106
  • McEwen The virulence of B. abortus for laboratory animals and pregnant cattle. Vet. Rec. 1940; 52:97-106
  • the 20th guinea pig passage of B. abortus strain 45 i.e. strain 45/20
  • conferred protective immunity conferred protective immunity
  • live strain 45/20 was injected into pregnant cows, it reverted to smooth pathogenic form that resulted in infection, abortion, and production of smooth agglutinins.
  • Taylor and McDiarmid (Taylor, P.W. Bactericidal and bacteriolytic activity of serum against gram-negative bacteria. Microbiol. Rev.
  • strain 45/20 and strain 19 in pregnant cows which demonstrated that clinical 45/20 and strain 19 in pregnant cows which demonstrated that clinical disease was caused by smooth revertants of strain 45/20 which required higher CO 2 for primary isolation.
  • whole cells of strain 45/20 combined with an adjuvant (K45/20A) have been used in cattle as a killed vaccine, but questionable protection and sporadic reversion of the organism to the smooth form during commercial fermentation often resulted in agglutination and complement fixation titers indistinguishable from field strain infection thereby, greatly reducing the use of this organism an effective vaccine (Ray, WC and Hendricks, JB. 45/20 Vaccination in a Brucella Infected Herd, Proc. Ann. Meeting USAHA. 78:88-103, 1974).
  • the instant invention claims a vaccine which provides protective immunity against pathogenic Brucella abortus and permits differentiation between vaccinated and field strain infected cattle.
  • the present invention is an improved vaccine against Brucella abortus which permits differentiation between vaccinated and field strain infected cattle.
  • the vaccine can be administered in two different forms: (1) cell envelopes isolated from an O polysaccharide antigen deficient, stable transposon mutant of B. abortus or (2) an O polysaccharide antigen deficient, stable transposon mutant of B. abortus.
  • One embodiment of this invention is a vaccine for providing protective immunity to a host animal against pathogenic Brucella abortus.
  • This vaccine comprises cell envelopes isolated from an O polysaccharide antigen deficient, stable transposon mutant of B. abortus, in an amount sufficient to induce protective immunity, together with a suitable carrier, wherein said cell envelopes contain intrinsic antigens of B. abortus except O polysaccharide antigen.
  • a further aspect of this invention is the vaccine comprising cell envelopes isolated from an O polysaccharide antigen deficient, stable transposon mutant of B. abortus, wherein said amount of cell envelopes ranges from about 400 ⁇ g to about 4000 ⁇ g.
  • Another embodiment of this invention is the above vaccine further comprising a suitable adjuvant.
  • a suitable adjuvant There are a variety of different adjuvants that would be suitable for the claimed vaccine and known to those skilled in the art. However, the Applicants prefer employing an adjuvant consisting essentially of 0.25 milligrams monophosphoryl lipid A, 0.25 milligrams Mycobacterium spp. cell wall skeleton, 0.25 milligrams of trehalose dimycolate, 120 milligrams of lecithin, 0.1 milliliters Drakeol 6VR, and 0.004 milliliters of Tween 80.
  • the claimed vaccine for providing protective immunity to a host animal against pathogenic Brucella abortus comprises cell envelopes isolated from an O polysaccharide antigen deficient, stable transposon mutant of B. abortus, in an amount ranging from about 400 ⁇ g to about 4000 ⁇ g, together with a suitable carrier, and these cell envelopes of the claimed vaccine contain intrinsic antigens of B. abortus except O polysaccharide antigen.
  • these cell envelopes of the claimed vaccine contain intrinsic antigens of B. abortus except O polysaccharide antigen.
  • the Applicants prefer to employ exposure of the transposon mutant to a sufficient dose of '"Cobalt radiation at 4° C to render the stable transposon mutant nonviable.
  • Nonviability is tested by standard methods known to those skilled in this art.
  • Another preferred aspect of the claimed invention is the method for isolating cell envelopes from the killed transposon mutants.
  • the Applicants prefer the methods described in detail in the specification. This procedure preserves intrinsic antigens of B. abortus.
  • Another embodiment of this invention are cell envelopes isolated from an O polysaccharide antigen deficient, stable transposon mutant of B. abortus that contain intrinsic antigens of B. abortus except O polysaccharide antigen.
  • An exemplary source for these cell envelopes is the O polysaccharide antigen deficient stable transposon mutant of B. abortus. 2308 m106 R::Tn5lacZ, having ATCC Accession No. 67912.
  • a further embodiment of this invention is a vaccine for providing protective immunity in a host animal against pathogenic Brucella abortus comprising an O polysaccharide antigen deficient, stable transposon mutant of B. abortus, in an amount sufficient to induce protective immunity.
  • this O polysaccharide antigen deficient, stable transposon mutant of B. abortus further contains intrinsic antigens of B. abortus except O polysaccharide antigen.
  • the preferred amount of stable transposon mutant ranges from about 10 9 to about 10 11 colony forming units.
  • an exemplary source of this stable transposon mutant is B. abortus 2308 m106 R::Tn5lacZ having ATCC Accession No. 67912.
  • Another aspect of the instant invention is the O polysaccharide antigen deficient, stable transposon mutant of B. abortus is further attenuated.
  • Yet another embodiment of this invention is an O polysaccharide antigen deficient, stable transposon mutant of Brucella abortus, wherein this transposon mutant contains intrinsic antigens of B. abortus except O polysaccharide antigen.
  • An exemplary source of an O polysaccharide antigen deficient, stable transposon mutant of Brucella abortus is B. abortus 2308 m106 R::Tn5lacZ, having ATCC Accession No. 67912.
  • Vaccines comprising cell envelopes from O polysaccharide antigen deficient, stable transposon mutants of B. abortus have the additional advantages of sterile immunity and nonpathogenicity to humans and animals. Therefore, individuals other than certified veterinarians can use the vaccines safely.
  • the use of live O polysaccharide antigen deficient, stable transposon mutants of B. abortus have the advantage of providing longer-lived immunity than killed bacteria.
  • the immunizing agent of the present invention can be in two forms. The following is a discussion of the preferred methods which can be used to create the different immunizing agents of this invention. It will be obvious to those skilled in the art that deviations from the procedures discussed below are possible without departing from the basic scope of the invention.
  • This example details the methods employed for vaccine production against Brucella abortus.
  • Brucella abortus Strain 19 was kindly provided by Dr. Billy
  • Brucella abortus Strain 19 and Brucella abortus Strain 2308 were maintained on potato infusion agar
  • PHA trypticase soy agar
  • TSA trypticase soy agar
  • a transposon mutant of strain 2308 Brucella abortus was isolated using the technique as described below. This transposon mutant, identified as Brucella abortus 2308 R::Tn5lacZ (m106), was deposited with the American Type Culture Collection and assigned ATCC Deposit No. 67912. This transposon mutant lacks O polysaccharide antigen common to smooth strains of Brucella abortus.
  • Pl and Mu phages were isolated from E. coli SF800 Pl::Tn5 lacZ karr and str S and E. coli CT151 kan R str S .
  • the E. coli CT151 contains die lysogenic bacteriophage Mu::Tn5(dl) kan R and str S .
  • the strains were isolated by streaking them out on LB (10g Bacto-tryptone, 5g yeast extract, 5g NaCl, pHed to 7.5) plates containing 40 micrograms/milliliters of kanamycin sulfate. The plates were then incubated at 30°C for 24 hours.
  • a single colony was selected and used to inoculate a 50 milliliter culture of LB broth containing 40 micrograms/milliliters of kanamycin sulfate.
  • the flasks were incubated overnight with a gentle agitation at 30oC.
  • the overnight culture was used to inoculate 500 milliliters of LB broth containing 5 mM CaCl 2 .
  • LB broth which was not pHed was used to avoid calcium precipitation.
  • CaCl 2 was also required for the CT151 strain growth.
  • the cultures were grown to an OD 600 of 0.4 and then rapidly warmed to 42°C by immersing the cultures in a 90oC water bath. The temperature was monitored using an ethanol rinsed thermometer. The culture flasks were placed in an air shaker and vigorously aerated at 42° C for 30 minutes and then cooled to a temperature of 38°C. The vigorous aeration was continued for approximately 90 minutes or until the cells were lysed. Temperatures was maintained above 37° C during this process to ensure that sufficient lysis occurs. Following lysis, the cultures were adjusted to 2% in CHCl 3 and agitated an additional 10 minutes to ensure complete lysis. The cell supernatant was then adjusted to 0.5 M in NaCl and chilled to 4°C.
  • the supernatant was kept at that temperature for at least 60 minutes. Bacterial debris was removed by centrifugation at 8000 rpm for 10 minutes. To ensure increased stability of the Mu bacteriophage, the following salts were added: 1-3 mM MgSO 4 and 1-3 mM Pb(OAc) 2 . Solid polyethylene glycol 8000 (PEG) was added to a final concentration of 10% (w/v) and the solution was incubated at 4°C for at least 60 minutes. The PEG precipitate was pelleted by centrifugation at 8000 rpm for 20 minutes.
  • PEG polyethylene glycol 8000
  • the pellet containing bacteriophage was resuspended in an ice cold Pl buffer (10 mM Tris-HCl, pH 7.6, 10 mM CaCl 2 ) or Mu buffer (10 mM Tris-HCl, pH 7.6, 1 mM MgSO 4 , 1mM Pb(OAc) 2 ) at 1/50 the original volume and kept on ice.
  • Pl buffer 10 mM Tris-HCl, pH 7.6, 10 mM CaCl 2
  • Mu buffer 10 mM Tris-HCl, pH 7.6, 1 mM MgSO 4 , 1mM Pb(OAc) 2
  • the bacteriophage bands were located by their opacity using a high intensity lamp and collected by side puncture of the tubes.
  • the harvested bacteriophage were dialyzed against three changes of 500 milliliters of PI and Mu buffers and stored at 4°C over CHCl 3 .
  • a confluent plate of Brucella abortus S-2308 was incubated for 48 hours at 37°C on potato infusion agar (PIA) or trypticase soy agar (TSA). The cells were then harvested from the plate into 5 milliliters of non-pHed tryptose broth adjusted to 10 mM CaCl 2 . The S-2308 cell suspension was diluted 100-fold prior to infection. To the tube containing the 1 : 100 dilution of the S-19 cells, 0.1 milliliters of the phage prepared as described above was added and incubated without agitation at 38°C for 30 minutes.
  • PIA potato infusion agar
  • TSA trypticase soy agar
  • the reaction was diluted two-fold with 1.0 milliliters of non-pHed tryptose broth (without CaCl 2 ).
  • the solution was transferred to a screw cap jar in a shaking water bath at a temperature of 38°C.
  • the mixture was incubated for 2 hours with vigorous agitation. Following the shaking, 0.4 milliliter aliquotes were spread onto PIA or TSA plates containing 25-40 micrograms/milliliters of kanamycin.
  • the plates were incubated at 38°C. Negative controls without bacteriophage were used in the experiment. The plates were checked beginning at day 3 and for as long as 14 days. Any colonies observed were picked and restreaked for isolation.
  • hybridization analysis using Tn5 DNA as a hybridization probe was performed as described by Southern, J. Mol. Biol.. 98:503-517 (1975). Briefly, genomic DNA from B. abortus was isolated by a rapid mini-prep method of lysis and restriction enzyme digestion. A confluent plate of B. abortus containing 1 X 10 11 cells was harvested in 5 ml of phenol saline (0.85% NaCl, 0.5% Phenol) heat killed at 80°C for at least 1 hour.
  • the cells were then pelleted by centrifugation at 5000 xg, and washed once with 5 ml of buffer A (10 mM Tris-HCl (pH 7.6), 1 M NaCl), and resuspended in buffer A prewarmed to 42 oC at a final concentration of 100 mg/ml(wet wt.) of cells.
  • the cells suspension was then mixed with an equal volume of a 42° C solution of 1.5% low melting point agarose in sterile, distilled water. The mixture was then molded in blocks (approximate volume 50-100 ⁇ l).
  • lysis buffer (6 mM Tris-HCl (pH 7.6), 1 M NaCl, 100 mM EDTA(pH 7.5), 0.5% sarkosyl (wt/vol.), 0.5% Brij-58 (vol/vol), and 0.2% deoxycholate (wt/vol.; filter sterilized) containing 1 mg/ml lysozyme and 20 ⁇ g/ml RNase A overnight at 37°C.
  • the lysing buffer was aspirated and the block incubated for 72 hours at 50°C in ESP buffer (0.5 M EDTA (pH 9.5), 1 % SDS and 2 mg/ml proteinase K).
  • the buffer was aspirated and the block incubated for 2-4 hours in high salt buffer with 10 mM Phenylmethyl-sulfonyl fluoride (PMSF) at room temperature, followed by an incubation in high salt buffer with ⁇ -mercaptoethanol (Biorad) at room temperature overnight.
  • PMSF Phenylmethyl-sulfonyl fluoride
  • Biorad ⁇ -mercaptoethanol
  • the plug was washed in two changes of sterile distilled water and melted in 0.5 ml of sterile distilled water at 70°C for 10 minutes, cooled to 37oC.
  • DNA digestion was performed according to the specification of the manufacturer (Boehringer, Mannheim, Biochemicals, Indianapolis, 1N). Electrophoretic separation of the fragments was then performed on 0.7% wt/vol. horizontal agarose gel (Maniatis, T.E., F. Fritsch, and J. Sambrook. 1982. Molecular cloning: a laboratory manual. Gold Spring Harbor Laboratory,
  • Bacteriophage lambda DNA was digested with Hindlll and used as molecular weight marker.
  • Plasmid pDJ13 containing Tn5 which codes for kanamycin resistance gene was purified from E. coli MM294 by CsCl gradient centrifugation.
  • the vector Pl phage was purified from E. coli MM294 (Miller, J.H. 1972. Experiments in molecular genetics. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY) and prepared by CsCl gradient centrifugation.
  • Genomic or plasmid restriction fragments were separated on the basis of size by agarose gel electrophoresis and ethidium bromide staining as described by Maniatis.
  • the transfer of DNA to nylon filtcrs was a modification of the technique of Southern (Southern,
  • Radioactive labeling of these DNA fragments to high specific activity was carried out as described by Feinberg and Volgestein (Feinberg, A.P. and B. Volgelstein. 1983. A technique of radio labeling DNA Restriction Endonuclease fragments to high specific activity. Analytical Biochemistry. 132:6-13).
  • the filter was then exposed to Kodak XAR-5 X-ray film. The autoradiograms were developed after 1-24 hours of incubation at -70°C. 3 ) SDS-Polyacrylamide gel electrophoresis
  • B. abortus S19 and mutants were grown on tryptose agar plates and suspended in phosphate buffered saline. Radiation killed B. abortus cells were centrifuged and pellets were solubilized in Laemmli sample buffer (2% SDS, 4% 2-B-mercaptoethanol, 10% glycerol, 1M Tris-HCl (pH 6.8), and 0.1 % bromophenol blue) and heated at 100°C for 10 minutes. Whole cell lysates and cell envelopes were subjected to SDS-PAGE using the Laemmli buffer system (Laemmli, U.K. 1970. Cleavage of structural proteins during assembly of bacteriophage T 4 .
  • Laemmli sample buffer 2% SDS, 4% 2-B-mercaptoethanol, 10% glycerol, 1M Tris-HCl (pH 6.8), and 0.1 % bromophenol blue
  • Phosphorylase b (94,000 molecular weight), bovine serum albumin (68,000 M.W), ovalbumin (43,000 M.W.) carbonic anhydrase (30,000 M.W), soybean trypsin inhibitor (21 ,000 M.W), and lysozyme (14,300 M.W) from Bio-Rad Laboratories were used as molecular mass standards. Gels were either stained with Coomassie blue R-250 (Sigma Chemical Co.) or were silver stained, using the Bio-Rad silver stain kit.
  • a mutant form of strain 2308 Brucella abortus has been created using the above technique and is identified as Brucella abortus 2308 R::Tn5lacZ (m106). This transposon mutant has been deposited with the
  • Bacteriophage Pl carrying Tn5lacZ was able to infect B. abortus, which is normally sensitive to kanamycin, resulting in insertion mutants that were kanamycin resistant (kan r ). These kan r insertion mutants arose at a frequency of transfer between 1-5 ⁇ 10 -10 per infected cell.
  • B. abortus mutants are not spontaneous mutants, and they all produced ⁇ -galactosidase because the transposon contain the lacZ gene. They were also sensitive to 5 ⁇ g ⁇ ml of streptomycin sulfate suggesting that streptomycin resistance encoded by Tn5 is not expressed in B. abortus. Similar observations were reported by Smith and Heffron.
  • LPS polymers can be dissociated into subunits by the detergent action of SDS and its mobility has been shown to be dependent on molecular size rather than intrinsic charge (Plava, E.T. and P.H. Makela. 1980. Lipopolysaccharide heterogeneity in
  • Salmonella typhimurium analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Eur. J. Biochem. 107:137-143; Sowa, et al., Electrophoresis. 7:283-288, 1986).
  • Monoclonal anti-O-antigen antibody (Montaraz, J.A., Winter, A.J., Hunter, D.M., Sowa, B.A., Wu, A.M., Adams, L.G., Protection Against Brucella abortus in mice with O-polysaccharide specific monoclonal antibodies, Infection and Immunity. 51:961-963, 1986; Sowa, et al, Electrophoresis. 7:283-288, 1986) reacted with immunoblots of SDS-PAGE of cell envelopes from strain 2308 with the typical multiple bands of LPS. Antibody reactivity was present in the high molecular weight region of the gel and reactivity was absent at the low molecular weight region of the gel.
  • Inhibition tests performed with purified O-antigen established that the O-antigen is a perosamine homopolymer (1,2 linked 4, 6 dideoxy-4-formamido-1-D-mannose) by nuclear resonance analysis.
  • Competitive inhibition assays of immunoblots demonstrated that 10 ⁇ g of purified O-antigen inhibited a 1:200 dilution of the O-antigen specific monoclonal antibody.
  • competitive inhibition ELISA (Montaraz, J.A., A.J. Winter, D.M. Hunter, B.A. Sowa, A.M. Wu, and L.G. Adams. 1986. Protection against Brucella abortus in Mice with O-polysaccharide-specific monoclonal antibodies. Infect. Immun. 51 :961-963) performed with soluble strain 19 antigen demonstrated that purified O-antigen inhibited the monoclonal antibody by 86%.
  • B. abortus cultures were maintained and identified by the techniques described in Laboratory Techniques in Brucellosis G. G. Alton, L.M. Jones, and D.E. Pietz, World Health Organization, Geneva, 1975, page 11-63.
  • the B. abortus strain 2308 m106 transposon mutant was maintained in kanamycin sulfate containing medium.
  • B. abortus Purity of B. abortus was maintained as given in Alton, Jones and Pietz (see reference above) with continual surveillance of colonial morphology by direct observation, crystal violet staining and bio typing for characteristics of the genus Brucella.
  • Virulence of Strain 19 was determined by inoculation of non-vaccinated pregnant first calf heifers by subcutaneous injection of 1 ⁇ 10 9 CFU and observing the heifers through a normal parturition.
  • Strain 2308 virulence was determined by conjunctival instillation of 1 ⁇ 10 7 CFU and observation for the effects on pregnancy which usually results in greater than 70% abortion with culture positive results from the fetal, placental and maternal tissues at parturition and necropsy. Strain 2308 M106 was non-pathogenic for pregnant goats (data presented in Example II). 3. Composition and Reaction of Media
  • the media used for B. abortus was prepared as follows:
  • Bacto-dextrose and Bacto-yeast extract were obtained from Difco Labs, Detroit, MI, peptone "M” was obtained from Pfizer Diagnostics Division, Chas. Pfizer & Co., New York, New York, sodium dihydrogen phosphates were obtained from Merck & Co., Inc., Rahway, N.J.
  • An ampoule of dried B. abortus seed was reconstituted with distilled water. This dried B. abortus seed was used to inoculate a number of potato agar slopes contained in tubes that were at least 20 ⁇ 150 mm in size and were placed at an angle while the medium was hardening so that the sloped surface of the medium is at least 50 mm long.
  • the inoculated slopes were incubated for 48 hours and used to seed production cultures.
  • the seed slopes were stored in the refrigerator at 4oC; generally they were stored for as long as 2-3 months before being used to seed production cultures. 6.
  • Seed cultures of B. abortus were removed from the 4oC refrigerator or from the -20°
  • the fermentation flask was inoculated with at least 1 ⁇ 10 11 CFU of B. abortus Strain 19, 2308 or 2308 M106 obtained by harvesting a 48-hour growth from a seed slope. Once inoculated, the fermentation flask was incubated at 37°C for 48 hours using the following rates for agitation and aeration. After 48 hours incubation, a sample was removed for examination and the brucellae were removed from the medium by centrifuging at 5000 x g.
  • the medium containing B. abortus was immediately (i.e. no more than 5 minutes) harvested by centrifugation at 5000 x g in a refrigerated centrifuge at 4°C. The supernatant was aspirated from the sediment while collecting the supernatant in a trap filtration flask. 4. Specification for Acceptable Harvest Material
  • Each individual 10-dose vial for cattle contained the following lyophilized adjuvant mixture:
  • Cell envelopes from B. abortus Strain 2308 M106 were prepared as follows. Cultures of Brucella abortus strain S2308 M106 were fermenter grown in Trypticase soy broth to an OD 550 of 106-133. The cells were harvested, rendered nonviable by irradiation with 1.38 Mrad of 60 Co gamma radiation at 4°C, and frozen at -20 °C. The cells were then thawed and subjected to osmotic and sonic shock to rupture the cells and purified cell envelopes were collected by the method described by J.F. Lutkenhaus, J. Bacteriol..
  • cell envelopes prepared as described above consist only of outer membrane-peptidoglycan complex (Sowa, et al., Vet. Microbio. 27:351-369, 1991).
  • OM-PG outer membrane-peptidoglycan
  • Protein content of cell envelope preparations of B. abortus 2308 M106 was determined by the Pierce
  • BCA bicinchoninic acid
  • the adjuvant solution was homogenized with the cell envelopes such that 1.0 ml of the adjuvant solution contained the quantities for each immunogen as given in Table 1 (below), and 10 mis of the emulsion was dispensed into single 10 ml crimped, rubber stoppered vaccine vials. Each dose was 1 ml and each vial contained ten one ml doses.
  • the sterility of the water solution and adjuvant material was determined by inoculation of 0.2 ml of the respective solutions onto 2% bovine blood nutrient agar plates and brucella agar nutrient agar with 5% bovine serum supplement and incubating for at least 5 days at 37°C.
  • the volume of fill for each vial was 10 mis.
  • the 10 ml of adjuvant/immunogen was dispensed by a multiple dose dispensing syringe and lyophilized with sealing and crimping done under vacuum.
  • the 10 mis of adjuvant/immunogen was dispensed by multi-dose dispensing syringe under a laminar flow hood and crimped and sealed with a rubber stopper. 8. Amount of Antigenic Material per Dose
  • the reconstituted cell envelopes of B. abortus Strain 2308 M106 contained 1,200.0 ⁇ g per 1.0 ml.
  • the immunogens were evaluated in cattle for their ability to induce significant protective immunity (p ⁇ 0.05) at 240 days post vaccination by challenge with pathogenic 1 ⁇ 10 7 CFU B. abortus S 2308 described as follows.
  • Randomization of treatment groups was done by the following manner. A total of 76 heifers were available for assignment to 3 treatment groups. Ear tag numbers were assigned to these heifers. Since the cattle were "worked through the pens" in a random manner, the ear tags were assigned sequentially as they are handled. A random number generator was used to assign the 76 cows to 3 intermediate groups. The 3 treatments were assigned numbers from 1 to 3 and assigned to groups using a random number table.
  • each heifer (at 130-200 days of gestation) was challenged by conjunctival instillation at 240 days post-vaccination with 10 7 CFU of standard USDA virulent B. abortus Strain 2308 and monitored until 420 days post-vaccination for: (1) abortion, (2) B. abortus culture of each fetus, placental membranes, milk and 50 tissues from necropsy of each dam, and (3) monthly serology pre- and post-vaccination and weekly serology post-challenge to include the card test, Rivanol test, complement fixation (CF) test, and rough and smooth enzyme-linked immunosorbent assay (ELISA).
  • the Brucellae are characterized by a number of phenotypic properties including colony type, antigenicity, virulence, growth rates, viability, resistance to antibiotics, and dye and salt sensitivity. Each of these characteristics has been found to vary individually but there is a high degree of association of changes in certain characteristics (Braun, W. Variation in the Genus Brucella. In Symposium on Brucellosis. AAAS,
  • Transposon mutant m106 was found to be stable in that it does not revert to the smooth, O polysaccharide containing B. abortus strain. Transposon mutant m106 was not maintained in or excreted by goats. This mutant did not stimulate anti-LPS antibodies which could confuse diagnosis.
  • Transposon mutant m106 was found to be stable in that it did not revert to smooth, O polysaccharide containing B. abortus strain as evidenced by:
  • ii) is not sex- or age-restricted, and
  • Brucella abortus outer membrane peptidoglycan (OM-PG, Group 3) sub-unit vaccine preparations prepared as described above were compared to adjuvant alone (negative control, Group 1) and Strain 19 (positive control, Group 2) treatment groups of pregnant heifers in an approved statistically valid protocol as given in Table 1 below.
  • ⁇ VWK Week pre- (-) or post- (+) vaccination
  • Tables 3-7 present data obtained from "adjuvant only” (negative control, "RADJ,” experimental group 1). The data are presented for each test (i.e. "ELR” is the rough indirect Brucella ELISA). Weeks 0,
  • Tables 8-12 present data obtained from "Strain 19" as the immunogen (positive control, "S19,” experimental group 2). The data are presented for each test (i.e. "ELR” is the rough indirect Brucella
  • Tables 13-17 present data obtained from "TN12x2" as the immunogen (cell envelopes isolated from transposon mutant M106, "TN12x2," experimental group 3). The data are scored and presented for each test (i.e. "ELR” is the rough indirect Brucella ELISA). One dose of 1,200 ⁇ g was given on day 0 and another dose of 1,200 ⁇ g was given on day 57 for a total of 2,400 ⁇ g (see Table 1 above). Weeks 0, 2, 4, 6, 8, 10, 13, 17, 21, 26, 30, 35 and 37 are presented in these tables. Numbers underneath the scores are the number of animals studied (e.g. "25") and the percentage of the total is presented in the parenthesis ("(96.2)").
  • Group 2 heifers vaccinated with Strain 19 had very high percentages of false positive serologic responses detected by the card (Table 10), complement fixation (Table 11) and rivanol (Table 12) tests beginning Week +2 post-vaccination. This group retained high diagnostic antibody titers through Week +37 post-vaccination. Indeed, one cow (number 1269) was persistently infected with Strain 19, thus producing sustained high levels of antibodies detected by standard USDA serodiagnostic tests. c. Cell Mediated Immune Responses
  • RB-51 is an O polysaccharide deficient mutant strain of B. abortus. Schurig et al. Biological properties of RB51; a stable rough strain of Brucella abortus. Vet. Microbiol.. 28:171-188.
  • Table 19 represent the in vitro lymphocyte responses of the same cattle to whole cell antigens of B. abortus strain 2308. These data also demonstrate significant numbers of responsive cattle in the groups that received of M106 OM-PG and in the group vaccinated with strain 19. For in vitro responses to these antigens, vaccination with strain 19 was statistically equivalent to vaccination with OM-PG.
  • Adjuvant 21 2 0 0 0 na na 23
  • Lymphocyte responsiveness can be induced by OM-PG of rough strains of B. abortus and (2) The apparent specificity of lymphocytes responding to immunization with OM-PG differs from those responding to strain 19 vaccination.
  • lymphocyte reactivities A summary of the lymphocyte reactivities is presented below.
  • table number 20 corresponds with table number 24 (calf)
  • table 21 corresponds with table 25
  • table 22 corresponds with table 26
  • table 23 corresponds with table 27.
  • M106 OM-PG induced statistically significant (p ⁇ 0.001) protection (87.5%) against fetal death, i.e. more living calves, as compared to non-vaccinated controls (45.8%). M106 OM-PG also stimulated more protective immunity against fetal death than did Strain 19 (80%), although not statistically significant. Neither Strain 19 (p ⁇ 0.057) nor M106 OM-PG (p ⁇ 0.508) produced statistically significant protection against infection as compared to non-vaccinated controls which reflects the severity of the experimental challenge. Additionally no statistical differences occurred when S19 was compared to M106 OM-PG with regard to protection against infection.
  • M106 OM-PG vaccine like Strain 19, greatly reduced the number of B. abortus reaching the fetus as compared to the Adjuvant negative control Group 1 (data not shown). This reduction significantly increased fetal survivability while permitting an increasing number of B. abortus to persist in the cow (data not shown). These data indicate that M106 OM-PG vaccinated cows would produce significantly more viable calves and shed fewer B. abortus into the environment. f. Safety and Toxicology Results
  • Intramuscular injections of the sub-unit rough (m106) cell envelope OM-PG B. abortus vaccine into cattle produced detectable granulomas at 60 days after the first injection, as well as for 30 days after the second injection. Of interest, all granulomas spontaneously resolved 60 days after the second injection. These data are presented in Tables 29 and 30.
  • the killed sub-unit OM-PG envelope vaccine did not stimulate significant cross reactivity on USDA card, Rivanol, or complement fixation diagnostic tests. This is in direct contrast to long term high levels of cross-reactive antibodies being stimulated by the standard USDA Strain 19 vaccine.
  • M106 OM-PG B. abortus vaccine potentially means that any serologic responses detected by the current standard USDA serodiagnostic tests would indicate field strain infection, thus permitting protection and differential diagnosis.

Abstract

The present invention is an improved vaccine against Brucella abortus which permits differentiation between vaccinated and field strain infected cattle. The vaccine can be administered in two different forms: (1) cell envelopes isolated from an O polysaccharide antigen deficient, stable transposon mutant of B. abortus or (2) an O polysaccharide antigen deficient, stable transposon mutant of B. abortus.

Description

IMPROVED VACCINE AGAINST BRUCELLA ABORTUS
The present invention relates to an improved vaccine against Brucella abortus. Specifically, the invention is a novel vaccine in which specific antigens of Brucella abortus induce an immunological response which provides protective immunity yet permits differentiation between field strain infected and vaccinated cattle. This novel vaccine is made from either an O polysaccharide antigen deficient transposon mutant of B. abortus or from cell envelopes isolated from such a transposon mutant. Brucella abortus are gram-negative coccobacilli that affect the reproductive system of cattle. The organism is a facultative intracellular parasite capable of causing spontaneous abortion, reduced milk production, delayed conception in cows and sterility in bulls. Brucellosis in humans and laboratory animals does not ordinarily involve the reproductive system. In these cases systemic dissemination of the organism occurs mainly through the blood to the reticuloendothelial system organs. The immunological response of the host can stop and reverse this invasive process. However, the ability of this organism to invade and survive within host macrophages compromises the ability of the host immune system to completely eliminate infection. This frequently results in the recurrence of infection with consequences identical to primary infection.
Stimulation of a protective immune response in cattle is achieved by vaccination with the live attenuated vaccine B. abortus strain 19, however, complete characterization of the mechanism of protective immunity has not been performed. Primary focus has been placed on the outer membrane components including lipopolysaccharide (LPS or O polysaccharide antigen), native hapten, polysaccharide B and outer membrane proteins (OMPs) (Bundle, D.R., J.W. Chenwonogrodzky, M. Caroff and M.B. Perry. 1978. The lipopolysaccharide of B. abortus and B. melitensis. Ann. Inst. Pasteur Microbiol. 38:92-98; Bundle, D.R., J.W. Chenwonogrodzky, and M.B. Perry. 1988. Characterization of brucella polysaccharide B. Infect.
Immun. 56:1101-1106; Moreno, E., H. Mayer, and I. Moriyon. 1987. Characterization of a native polysaccharide hapten from Brucella melitensis. Infect. Immun. 55:2850-2853; Moreno, E., M.W. Pitt, L.M. Jones, G.G. Schurig and O.T. Bermann. 1979. Purification and characterization of smooth and rough lipopolysaccharides from Brucella abortus. J. Bacteriol. 138:3361-369; Moreno, E., L.S. Speth, L.M. Jones and D.T. Berman. 1981. Immunochemical characterization of Brucella lipopolysaccharides and polysaccharides. Infect. Immun. 31:214-222). LPS consists of an hydrophobic lipid A region, the oligosaccharide core and the O-polysaccharide side chain which gives the cell surface its hydrophilic character. Native hapten which has recently been identified as the O-polysaccharide (Moreno, E., H. Mayer, and I. Moriyon. 1987. Characterization of a native polysaccharide hapten from Brucella melitensis. Infect. Immun. 55:2850-2853) and polysaccharide B is a complex mixture of low molecular weight glucans (Bundle, D.R., J.W. Chenwonogrodzky, and M.B. Perry. 1988. Characterization of brucella polysaccharide B. Infect. Immun. 56:1101-1106). Of these components, the O-polysaccharide side chain of the LPS is the most antigenic and has been shown to elicit a protective immune response in the mouse model (Montaraz, J.A.,
A.J. Winter, D.M. Hunter, B.A. Sowa, A.M. Wu, and L.G. Adams. 1986. Protection against Brucella abortus in Mice with O-polysaccharide-specific monoclonal antibodies. Infect. Immun. 51:961-963).
However, it has also been demonstrated that the presence of LPS increases intracellular survival, presumably by blocking or actively inhibiting macrophage function (Harmon, D.G., L.G. Adams, and M. Frey. 1988. Survival of rough and smooth strains of Brucella abortus in bovine mammary gland macrophages. Am. J.
Vet. Res. 49:1092-1097: Price, R.E., J.W. Templeton, and L.G. Adams. 1990. Survival of smooth, rough and transposon mutant strains of Brucella abortus in bovine mammary macrophages. Vet. Immunol.
Immunopath. 26:353-365; Price, R.E., J.W. Templeton, R. Smith III, and L.G. Adams. 1990. Ability of mononuclear phagocytes from cattle naturally resistant or susceptible to brucellosis to control in vitro intracellular survival of Brucella abortus. Infect Immun. 58:879-886).
To reduce the incidence and economic loss caused by bovine brucellosis, several different vaccines have been used in the past. The vaccines are generally prepared using either live or killed strains of Brucella. The most common of these is strain 19. The use of these vaccines has several disadvantages. One disadvantage is that currently there is no consistently effective means for distinguishing strain 19 vaccinated cattle from those infected by pathogenic strains of Brucella abortus. Both the vaccine and the pathogenic strain cause the production of cross-reacting antibodies which serve as the basis for current serological tests for brucellosis. Other disadvantages of some of the killed vaccines include: the need to inject the vaccine twice; the instability of several of the strains used to create the vaccines; the vaccines frequently cause large tissue reactions at the site of injection; the immunity induced is also short lived; and the protective immunity is suboptimal. Crude protein derivatives have also been used experimentally to produce protective immunity.
These crude extracts have the same disadvantages as the killed and live vaccines. Additionally, the extracts are crude and contain cellular components not required to induce protective immunity. This can cause further confusion in differentiating between vaccinated and field strain infected cattle. In the early 1920's McEwen (McEwen, A.D., R.S. Roberts. Bovine contagious abortion. The use of guinea-pigs in immunization studies. J. Comp. Pathol. Ther. 1936, 49:97-117) isolated smooth B. abortus strain 45 from cattle which demonstrated to be relatively avirulent yet stimulate protective immunity in guinea pigs. While attempting to restore virulence to strain 45 by serial passage through guinea pigs, McEwen (McEwen, A.D. The virulence of B. abortus for laboratory animals and pregnant cattle. Vet. Rec. 1940; 52:97-106) discovered that the 20th guinea pig passage of B. abortus strain 45, i.e. strain 45/20, conferred protective immunity; however, when live strain 45/20 was injected into pregnant cows, it reverted to smooth pathogenic form that resulted in infection, abortion, and production of smooth agglutinins. Taylor and McDiarmid (Taylor, P.W. Bactericidal and bacteriolytic activity of serum against gram-negative bacteria. Microbiol. Rev. 1983; 47:46-83) later compared intravenous injections of strain 45/20 and strain 19 in pregnant cows which demonstrated that clinical 45/20 and strain 19 in pregnant cows which demonstrated that clinical disease was caused by smooth revertants of strain 45/20 which required higher CO2 for primary isolation. Additionally, whole cells of strain 45/20 combined with an adjuvant (K45/20A) have been used in cattle as a killed vaccine, but questionable protection and sporadic reversion of the organism to the smooth form during commercial fermentation often resulted in agglutination and complement fixation titers indistinguishable from field strain infection thereby, greatly reducing the use of this organism an effective vaccine (Ray, WC and Hendricks, JB. 45/20 Vaccination in a Brucella Infected Herd, Proc. Ann. Meeting USAHA. 78:88-103, 1974).
The instant invention claims a vaccine which provides protective immunity against pathogenic Brucella abortus and permits differentiation between vaccinated and field strain infected cattle.
The present invention is an improved vaccine against Brucella abortus which permits differentiation between vaccinated and field strain infected cattle. The vaccine can be administered in two different forms: (1) cell envelopes isolated from an O polysaccharide antigen deficient, stable transposon mutant of B. abortus or (2) an O polysaccharide antigen deficient, stable transposon mutant of B. abortus.
One embodiment of this invention is a vaccine for providing protective immunity to a host animal against pathogenic Brucella abortus. This vaccine comprises cell envelopes isolated from an O polysaccharide antigen deficient, stable transposon mutant of B. abortus, in an amount sufficient to induce protective immunity, together with a suitable carrier, wherein said cell envelopes contain intrinsic antigens of B. abortus except O polysaccharide antigen.
The Applicants prefer isolating cell envelopes from the exemplary O polysaccharide antigen deficient, stable transposon mutant of B. abortus. 2308 m106 R::Tn5lacZ, having ATCC Accession No. 67912.
A further aspect of this invention is the vaccine comprising cell envelopes isolated from an O polysaccharide antigen deficient, stable transposon mutant of B. abortus, wherein said amount of cell envelopes ranges from about 400 μg to about 4000 μg.
Another embodiment of this invention is the above vaccine further comprising a suitable adjuvant. There are a variety of different adjuvants that would be suitable for the claimed vaccine and known to those skilled in the art. However, the Applicants prefer employing an adjuvant consisting essentially of 0.25 milligrams monophosphoryl lipid A, 0.25 milligrams Mycobacterium spp. cell wall skeleton, 0.25 milligrams of trehalose dimycolate, 120 milligrams of lecithin, 0.1 milliliters Drakeol 6VR, and 0.004 milliliters of Tween 80.
More specifically, the claimed vaccine for providing protective immunity to a host animal against pathogenic Brucella abortus comprises cell envelopes isolated from an O polysaccharide antigen deficient, stable transposon mutant of B. abortus, in an amount ranging from about 400 μg to about 4000 μg, together with a suitable carrier, and these cell envelopes of the claimed vaccine contain intrinsic antigens of B. abortus except O polysaccharide antigen. There are a variety of different methods known to those skilled in this art for killing the stable transposon mutant of the claimed invention. However, the Applicants prefer to employ exposure of the transposon mutant to a sufficient dose of '"Cobalt radiation at 4° C to render the stable transposon mutant nonviable. Nonviability is tested by standard methods known to those skilled in this art. Another preferred aspect of the claimed invention is the method for isolating cell envelopes from the killed transposon mutants. The Applicants prefer the methods described in detail in the specification. This procedure preserves intrinsic antigens of B. abortus.
Another embodiment of this invention are cell envelopes isolated from an O polysaccharide antigen deficient, stable transposon mutant of B. abortus that contain intrinsic antigens of B. abortus except O polysaccharide antigen. An exemplary source for these cell envelopes is the O polysaccharide antigen deficient stable transposon mutant of B. abortus. 2308 m106 R::Tn5lacZ, having ATCC Accession No. 67912. A further embodiment of this invention is a vaccine for providing protective immunity in a host animal against pathogenic Brucella abortus comprising an O polysaccharide antigen deficient, stable transposon mutant of B. abortus, in an amount sufficient to induce protective immunity. More specifically, this O polysaccharide antigen deficient, stable transposon mutant of B. abortus further contains intrinsic antigens of B. abortus except O polysaccharide antigen. For the claimed invention, the preferred amount of stable transposon mutant ranges from about 109 to about 1011 colony forming units. Additionally, an exemplary source of this stable transposon mutant is B. abortus 2308 m106 R::Tn5lacZ having ATCC Accession No. 67912. Another aspect of the instant invention is the O polysaccharide antigen deficient, stable transposon mutant of B. abortus is further attenuated. Yet another embodiment of this invention is an O polysaccharide antigen deficient, stable transposon mutant of Brucella abortus, wherein this transposon mutant contains intrinsic antigens of B. abortus except O polysaccharide antigen. An exemplary source of an O polysaccharide antigen deficient, stable transposon mutant of Brucella abortus is B. abortus 2308 m106 R::Tn5lacZ, having ATCC Accession No. 67912. Vaccines comprising cell envelopes from O polysaccharide antigen deficient, stable transposon mutants of B. abortus have the additional advantages of sterile immunity and nonpathogenicity to humans and animals. Therefore, individuals other than certified veterinarians can use the vaccines safely. The use of live O polysaccharide antigen deficient, stable transposon mutants of B. abortus have the advantage of providing longer-lived immunity than killed bacteria.
As noted above, the immunizing agent of the present invention can be in two forms. The following is a discussion of the preferred methods which can be used to create the different immunizing agents of this invention. It will be obvious to those skilled in the art that deviations from the procedures discussed below are possible without departing from the basic scope of the invention.
EXAMPLE I Methods Employed for Production of
Vaccines against Brucella abortus
This example details the methods employed for vaccine production against Brucella abortus.
SOURCES AND MICROORGANISMS USED FOR PRODUCTION OF NON- VIABLE SUBUNIT VACCINE AGAINST B. ABORTUS
1. Source
Brucella abortus Strain 19, and Brucella abortus Strain 2308 were kindly provided by Dr. Billy
Deyoe (USDA/ARS/NADC, Ames, IA.) and Strain 2308 M106 was produced by following the protocol set forth below.
2. Microorganisms
Brucella abortus Strain 19 and Brucella abortus Strain 2308 were maintained on potato infusion agar
(PLA) plates and were grown to confiuency on trypticase soy agar (TSA) plates for 48 hours at 37° C in an atmosphere of air containing 5 % CO2. Growth from each plate was harvested into 5 ml of peptone saline (1 % Bacto-peptone, 0.5% NaCl) before use. A transposon mutant of strain 2308 Brucella abortus was isolated using the technique as described below. This transposon mutant, identified as Brucella abortus 2308 R::Tn5lacZ (m106), was deposited with the American Type Culture Collection and assigned ATCC Deposit No. 67912. This transposon mutant lacks O polysaccharide antigen common to smooth strains of Brucella abortus. Cell envelopes isolated from m106 transposon mutant has been used as an immunizing agent to create a Brucella abortus vaccine which provides protective immunity, yet still permits differentiation between field strain infected and vaccinated cattle (Data presented in Example III). The live transposon mutant m106 is currently being used as an immunizing agent to create a Brucella abortus vaccine which provides protective immunity, yet still permits differentiation between field strain infected and vaccinated cattle. This study with the live transposon mutant m106 is similar to the current practice using strain 19. 3. Production and Characterization of Transposon Mutants Vaccine Strains of Brucella abortus Strain 2308
(a) Introduction
A method for producing immunizing agents against Brucella abortus which induces an
immunological reaction against Brucella abortus and still permits differentiation between vaccinated and field strain infected cattle was achieved through the development of transposon mutants. The mutants were developed through Pl and Mu phage infections of Brucella abortus. The methods employed utilized the capacity of the broad range bacteriophage Pl of Escherichia coli to deliver the transposon to B. abortus S2308 via mating with E. coli carrying the broad range plasmid derivative of RK2 (Smith, L.D., and F. Heffron. 1987. Transposon Tn5 mutagenesis of Brucella abortus. Infect. Immun. 55:2774-2776). Smith and Heffron suggested that Pl infection preferentially selects rough-cell variants which arise spontaneously in in vitro cultures due to increased surface for attachment.
(b) Methods for Producing Transposon Mutants
Pl and Mu phages were isolated from E. coli SF800 Pl::Tn5 lacZ karr and strS and E. coli CT151 kanR strS. The E. coli CT151 contains die lysogenic bacteriophage Mu::Tn5(dl) kanR and strS. The strains were isolated by streaking them out on LB (10g Bacto-tryptone, 5g yeast extract, 5g NaCl, pHed to 7.5) plates containing 40 micrograms/milliliters of kanamycin sulfate. The plates were then incubated at 30°C for 24 hours. A single colony was selected and used to inoculate a 50 milliliter culture of LB broth containing 40 micrograms/milliliters of kanamycin sulfate. The flasks were incubated overnight with a gentle agitation at 30ºC. The overnight culture was used to inoculate 500 milliliters of LB broth containing 5 mM CaCl2. LB broth which was not pHed was used to avoid calcium precipitation. CaCl2 was also required for the CT151 strain growth.
The cultures were grown to an OD600 of 0.4 and then rapidly warmed to 42°C by immersing the cultures in a 90ºC water bath. The temperature was monitored using an ethanol rinsed thermometer. The culture flasks were placed in an air shaker and vigorously aerated at 42° C for 30 minutes and then cooled to a temperature of 38°C. The vigorous aeration was continued for approximately 90 minutes or until the cells were lysed. Temperatures was maintained above 37° C during this process to ensure that sufficient lysis occurs. Following lysis, the cultures were adjusted to 2% in CHCl3 and agitated an additional 10 minutes to ensure complete lysis. The cell supernatant was then adjusted to 0.5 M in NaCl and chilled to 4°C. The supernatant was kept at that temperature for at least 60 minutes. Bacterial debris was removed by centrifugation at 8000 rpm for 10 minutes. To ensure increased stability of the Mu bacteriophage, the following salts were added: 1-3 mM MgSO4 and 1-3 mM Pb(OAc)2. Solid polyethylene glycol 8000 (PEG) was added to a final concentration of 10% (w/v) and the solution was incubated at 4°C for at least 60 minutes. The PEG precipitate was pelleted by centrifugation at 8000 rpm for 20 minutes. The pellet containing bacteriophage was resuspended in an ice cold Pl buffer (10 mM Tris-HCl, pH 7.6, 10 mM CaCl2) or Mu buffer (10 mM Tris-HCl, pH 7.6, 1 mM MgSO4, 1mM Pb(OAc)2) at 1/50 the original volume and kept on ice. For each 3.5 milliliters of resuspended PEG pellet, 2.4 grams of solid CsCl was added and the resulting solution was centrifuged to equilibrium for 24 hours in an 80Ti rotor at 38,000 rpm at a temperature of 5°C. The bacteriophage bands were located by their opacity using a high intensity lamp and collected by side puncture of the tubes. The harvested bacteriophage were dialyzed against three changes of 500 milliliters of PI and Mu buffers and stored at 4°C over CHCl3. (1) Infection of Brucella abortus With Pl and Mu Phage
A confluent plate of Brucella abortus S-2308 was incubated for 48 hours at 37°C on potato infusion agar (PIA) or trypticase soy agar (TSA). The cells were then harvested from the plate into 5 milliliters of non-pHed tryptose broth adjusted to 10 mM CaCl2. The S-2308 cell suspension was diluted 100-fold prior to infection. To the tube containing the 1 : 100 dilution of the S-19 cells, 0.1 milliliters of the phage prepared as described above was added and incubated without agitation at 38°C for 30 minutes. The reaction was diluted two-fold with 1.0 milliliters of non-pHed tryptose broth (without CaCl2). The solution was transferred to a screw cap jar in a shaking water bath at a temperature of 38°C. The mixture was incubated for 2 hours with vigorous agitation. Following the shaking, 0.4 milliliter aliquotes were spread onto PIA or TSA plates containing 25-40 micrograms/milliliters of kanamycin. The plates were incubated at 38°C. Negative controls without bacteriophage were used in the experiment. The plates were checked beginning at day 3 and for as long as 14 days. Any colonies observed were picked and restreaked for isolation. Colonies so isolated were characterized as outlined below (Alton, Laboratory Techniques in Brucellosis. World Health Organization, Geneva 64-66 (1975). Stock suspensions were stored in 50% glycerol at -70°C. (c) Identification of Transposon Mutant Genotype
1 ) DNA isolation
To identify the genetic lesion caused by transposon mutagenesis, hybridization analysis using Tn5 DNA as a hybridization probe was performed as described by Southern, J. Mol. Biol.. 98:503-517 (1975). Briefly, genomic DNA from B. abortus was isolated by a rapid mini-prep method of lysis and restriction enzyme digestion. A confluent plate of B. abortus containing 1 X 1011 cells was harvested in 5 ml of phenol saline (0.85% NaCl, 0.5% Phenol) heat killed at 80°C for at least 1 hour. The cells were then pelleted by centrifugation at 5000 xg, and washed once with 5 ml of buffer A (10 mM Tris-HCl (pH 7.6), 1 M NaCl), and resuspended in buffer A prewarmed to 42 ºC at a final concentration of 100 mg/ml(wet wt.) of cells. The cells suspension was then mixed with an equal volume of a 42° C solution of 1.5% low melting point agarose in sterile, distilled water. The mixture was then molded in blocks (approximate volume 50-100 μl). Each block was then incubated in lysis buffer (6 mM Tris-HCl (pH 7.6), 1 M NaCl, 100 mM EDTA(pH 7.5), 0.5% sarkosyl (wt/vol.), 0.5% Brij-58 (vol/vol), and 0.2% deoxycholate (wt/vol.; filter sterilized) containing 1 mg/ml lysozyme and 20 μg/ml RNase A overnight at 37°C. The lysing buffer was aspirated and the block incubated for 72 hours at 50°C in ESP buffer (0.5 M EDTA (pH 9.5), 1 % SDS and 2 mg/ml proteinase K). The buffer was aspirated and the block incubated for 2-4 hours in high salt buffer with 10 mM Phenylmethyl-sulfonyl fluoride (PMSF) at room temperature, followed by an incubation in high salt buffer with β-mercaptoethanol (Biorad) at room temperature overnight.
The plug was washed in two changes of sterile distilled water and melted in 0.5 ml of sterile distilled water at 70°C for 10 minutes, cooled to 37ºC. DNA digestion was performed according to the specification of the manufacturer (Boehringer, Mannheim, Biochemicals, Indianapolis, 1N). Electrophoretic separation of the fragments was then performed on 0.7% wt/vol. horizontal agarose gel (Maniatis, T.E., F. Fritsch, and J. Sambrook. 1982. Molecular cloning: a laboratory manual. Gold Spring Harbor Laboratory,
Cold Spring Harbor, NY). Bacteriophage lambda DNA was digested with Hindlll and used as molecular weight marker. Plasmid pDJ13 containing Tn5 which codes for kanamycin resistance gene, was purified from E. coli MM294 by CsCl gradient centrifugation. The vector Pl phage was purified from E. coli MM294 (Miller, J.H. 1972. Experiments in molecular genetics. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY) and prepared by CsCl gradient centrifugation.
2) Electrophoresis of DNA and Hybridization reactions
Genomic or plasmid restriction fragments were separated on the basis of size by agarose gel electrophoresis and ethidium bromide staining as described by Maniatis. The transfer of DNA to nylon filtcrs (Zeta-probe, Bio-Rad Lab., Richmond, Calif.) was a modification of the technique of Southern (Southern,
E.M. 1975. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J. Mol. Biol. 98:503-517). Filters were prehybridized with 30 ml buffer (1.5 XSSPE, 1.0% wt/vol. SDS, 0.5% wt/vol. Blotto, 100 μg/ml denatured salmon sperm DNA) for 16 hours at 68ºC. DNA was probed with either a 12kb Bam HI-HindIII fragment constructed in pBR322 and containing Pl ::Tn5lacZ or a 3.3kb HindIII fragment isolated from pDJ13 that contains the gene encoding neomycin phospotransferase II. Radioactive labeling of these DNA fragments to high specific activity was carried out as described by Feinberg and Volgestein (Feinberg, A.P. and B. Volgelstein. 1983. A technique of radio labeling DNA Restriction Endonuclease fragments to high specific activity. Analytical Biochemistry. 132:6-13). The filter was then exposed to Kodak XAR-5 X-ray film. The autoradiograms were developed after 1-24 hours of incubation at -70°C. 3 ) SDS-Polyacrylamide gel electrophoresis
One dimensional gel analysis was performed on bacterial whole cell lysates and cell envelope preparations of B. abortus as described by Sowa, et al (Sowa, B.A. , R.P. Crawford, F.C. Heck, J.D.
Williams, A.M. Wu, K.A. Kelly, L.G. Adams. 1986. Size, charge and structural heterogeneity of Brucella abortus lipopolysaccharides demonstrated by two-dimensional gel electrophoresis. Electrophoresis, 7:283-28).
B. abortus S19 and mutants were grown on tryptose agar plates and suspended in phosphate buffered saline. Radiation killed B. abortus cells were centrifuged and pellets were solubilized in Laemmli sample buffer (2% SDS, 4% 2-B-mercaptoethanol, 10% glycerol, 1M Tris-HCl (pH 6.8), and 0.1 % bromophenol blue) and heated at 100°C for 10 minutes. Whole cell lysates and cell envelopes were subjected to SDS-PAGE using the Laemmli buffer system (Laemmli, U.K. 1970. Cleavage of structural proteins during assembly of bacteriophage T4. Nature (London), 227:680-685) with a 4% (w/v) stacking gel and 12.5% (w/v) separating gel. Phosphorylase b (94,000 molecular weight), bovine serum albumin (68,000 M.W), ovalbumin (43,000 M.W.) carbonic anhydrase (30,000 M.W), soybean trypsin inhibitor (21 ,000 M.W), and lysozyme (14,300 M.W) from Bio-Rad Laboratories were used as molecular mass standards. Gels were either stained with Coomassie blue R-250 (Sigma Chemical Co.) or were silver stained, using the Bio-Rad silver stain kit.
Stained gels were then photographed without drying.
(d) Characterization Studies of Transposon Mutant
A mutant form of strain 2308 Brucella abortus has been created using the above technique and is identified as Brucella abortus 2308 R::Tn5lacZ (m106). This transposon mutant has been deposited with the
American Type Culture Collection and been assigned ATCC Deposit No. 67912. Specific characteristics of this mutant were analyzed and are presented below. 1) Isolation of kanam vein-resistant B. abortus mutants
Bacteriophage Pl carrying Tn5lacZ, was able to infect B. abortus, which is normally sensitive to kanamycin, resulting in insertion mutants that were kanamycin resistant (kanr). These kanr insertion mutants arose at a frequency of transfer between 1-5 × 10-10 per infected cell.
Over 100 stable insertion mutants selected on TSA agar supplemented with kanamycin have been isolated. Using this method all mutants were resistant to 40 μg/ml of kanamycin sulfate suggesting that these
B. abortus mutants are not spontaneous mutants, and they all produced β-galactosidase because the transposon contain the lacZ gene. They were also sensitive to 5 μg\ml of streptomycin sulfate suggesting that streptomycin resistance encoded by Tn5 is not expressed in B. abortus. Similar observations were reported by Smith and Heffron.
Characterization of these independent insertion mutants were performed using classical biotyping in order to confirm their identity as B. abortus and to isolate mutants with peculiar phenotype traits. 2) DNA Analyses of Transposon Mutants of B. abortus
Southern blot hybridization of DNA restriction fragments demonstrated that a single copy of Tn5 was inserted into the genomic DNA of mutants. Genomic DNA was prepared and digested with several restriction endonucleases. The DNA restriction fragments were separated by electrophoresis and transferred to nylon (Zeta-Bind) by Southern blotting. There is one EcoRI, one Hind III and BamHI site in Tn5lacZ (Berg, D.E., R. Joregensen, and J. Davies. 1978. Transposablekanamycin-neomycin resistance determinants. In Microbiology - 1978 (ed. D. Schlessinger), p. 13. American Society for Microbiology, Washington, D.C.; Jorgensen, R.A., S.J., Rothstein, and W.S. Rezuikoff. 1979. A restriction enzyme cleavage map of Tn5 and location of a region encoding neomycin resistance. Mol. Gen. Genet. 177:65), therefore digestion of genomic DNA by EcoRI, Hind III or BamHI should yield two DNA fragments that contain the left and right portions of Tn5lacZ for each site of insertion. When the 12kb Bam HI-HindIII fragment was used as a probe, two bands were observed.
To ensure that the mutant contained only Tn5lacZ and was not a lysogen of Pl , Southern hybridization was repeated with Pl phage DNA. The mutants failed to form hybrids with DNA from Phage Pl (data not shown). Because sequences homologous to Tn5lacZ are not present in the control strain 19 and kanamycin resistant insertion mutants do not contain Pl DNA sequences, it is evident that the mutants acquired Tn5lacZ by Pl ::Tn5lacZ infection followed by transposition of Tn5lacZ from the phage Pl vector and by loss of the Pl vector from the lineage.
These data indicated the isolation of a Brucella transposon mutant which exhibited characteristics of rough O polysaccharide deficient strain and retained the properties of the parent strain 2308. Removal of the transposon has not been possible either in vivo or in vitro.
To decipher the structure of the LPS responsible for the atypical behavior of the mutant cell envelopes was characterized using SDS-polyacrylamide gel electrophoresis. LPS polymers can be dissociated into subunits by the detergent action of SDS and its mobility has been shown to be dependent on molecular size rather than intrinsic charge (Plava, E.T. and P.H. Makela. 1980. Lipopolysaccharide heterogeneity in
Salmonella typhimurium analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Eur. J. Biochem. 107:137-143; Sowa, et al., Electrophoresis. 7:283-288, 1986).
3) One Dimensional SDS-PAGE of Transposon Mutants of B. abortus Silver staining of cell envelope preparations from smooth and rough strains of Brucella and the mutant on 12.5% polyacrylamide gels demonstrated that each LPS entity gives a single somewhat diffuse band of characteristic mobility. The smooth strain B. abortus 2308 showed a set of bands which appeared as a broad diffuse band when stained with silver. The pattern of the bands of rough strain 45/20 were fast migrating. The mutant, S2308 M106::Tn5LacZ demonstrated no detectable bands and resembled other rough O polysaccharide antigen deficient strains of B. abortus. 4) Monoclonal Binding to Transposon Mutants of B. abortus
Monoclonal anti-O-antigen antibody (Montaraz, J.A., Winter, A.J., Hunter, D.M., Sowa, B.A., Wu, A.M., Adams, L.G., Protection Against Brucella abortus in mice with O-polysaccharide specific monoclonal antibodies, Infection and Immunity. 51:961-963, 1986; Sowa, et al, Electrophoresis. 7:283-288, 1986) reacted with immunoblots of SDS-PAGE of cell envelopes from strain 2308 with the typical multiple bands of LPS. Antibody reactivity was present in the high molecular weight region of the gel and reactivity was absent at the low molecular weight region of the gel. Inhibition tests performed with purified O-antigen established that the O-antigen is a perosamine homopolymer (1,2 linked 4, 6 dideoxy-4-formamido-1-D-mannose) by nuclear resonance analysis. Competitive inhibition assays of immunoblots demonstrated that 10 μg of purified O-antigen inhibited a 1:200 dilution of the O-antigen specific monoclonal antibody. In addition, competitive inhibition ELISA (Montaraz, J.A., A.J. Winter, D.M. Hunter, B.A. Sowa, A.M. Wu, and L.G. Adams. 1986. Protection against Brucella abortus in Mice with O-polysaccharide-specific monoclonal antibodies. Infect. Immun. 51 :961-963) performed with soluble strain 19 antigen demonstrated that purified O-antigen inhibited the monoclonal antibody by 86%.
In contrast, S2308 M106::Tn5LacZ did not react with O-antigen specific monoclonal antibody. The lack of reactivity of this antibody with this transposon mutant strain is consistent with the absence of O polysaccharide antigen. B. METHODS EMPLOYED FOR MAINTAINING CULTURES
1. Maintenance and Identification
B. abortus cultures were maintained and identified by the techniques described in Laboratory Techniques in Brucellosis G. G. Alton, L.M. Jones, and D.E. Pietz, World Health Organization, Geneva, 1975, page 11-63. The B. abortus strain 2308 m106 transposon mutant was maintained in kanamycin sulfate containing medium.
2. Virulence and Purity of Cultures
Purity of B. abortus was maintained as given in Alton, Jones and Pietz (see reference above) with continual surveillance of colonial morphology by direct observation, crystal violet staining and bio typing for characteristics of the genus Brucella.
Virulence of Strain 19 was determined by inoculation of non-vaccinated pregnant first calf heifers by subcutaneous injection of 1 × 109 CFU and observing the heifers through a normal parturition.
Strain 2308 virulence was determined by conjunctival instillation of 1 × 107 CFU and observation for the effects on pregnancy which usually results in greater than 70% abortion with culture positive results from the fetal, placental and maternal tissues at parturition and necropsy. Strain 2308 M106 was non-pathogenic for pregnant goats (data presented in Example II). 3. Composition and Reaction of Media
The media used for B. abortus was prepared as follows:
Bacto-dextrose 30.0g
peptone "M" 30.0g
Bacto-yeast extract 10.0g
sodium dihydrogen phosphates 9.0g
disodium hydrogen phosphate (anhydrous) 3.3g
distilled water 1 liter
While mixing, the water was brought just to boiling and peptone "M" was added. The solution was allowed to simmer for 15 minutes and then allowed to cool for 10 minutes. While mixing, dextrose, yeast extract, sodium dihydrogen phosphate, and disodium hydrogen phosphate are then added. The solution was cooled for about 30 minutes, the pH (about 6.4) was checked and the 800 ml of medium was filtered into the 1 liter fermentation flask. The hose was removed from the medium inlet port and the port was immediately covered with cotton saturated with 70% ethanol. The sterile cap was removed from the beaker and placed on the medium inlet port of die fermentation flask containing 10 ml of distilled water and 0.4 ml of anti-foam 60 silicone emulsion. Bacto-dextrose and Bacto-yeast extract were obtained from Difco Labs, Detroit, MI, peptone "M" was obtained from Pfizer Diagnostics Division, Chas. Pfizer & Co., New York, New York, sodium dihydrogen phosphates were obtained from Merck & Co., Inc., Rahway, N.J.
4. Character, Size, and Shape of Container
B. abortus cultures were grown in a 1 liter cylindrical Asti Scientific Zworts Co. fermentation flask with computer controllable pH, CO2, and temperature.
5. Storage Conditions of Seed Cultures
An ampoule of dried B. abortus seed was reconstituted with distilled water. This dried B. abortus seed was used to inoculate a number of potato agar slopes contained in tubes that were at least 20 × 150 mm in size and were placed at an angle while the medium was hardening so that the sloped surface of the medium is at least 50 mm long.
The inoculated slopes were incubated for 48 hours and used to seed production cultures. The seed slopes were stored in the refrigerator at 4ºC; generally they were stored for as long as 2-3 months before being used to seed production cultures. 6. Methods of Preparing Suspensions for Seeding or Inoculation
B. abortus organisms were grown on potato agar which had uniform smooth colony characteristics as determined by crystal-violet staining for Strain 2308. Consistently rough 2308 M106 colonies are suspended in peptone-saline solution for enumeration of organisms in the suspension by serial-dilution plate counts.
7. Technique of Inoculating Seed and Production Media
Seed cultures of B. abortus were removed from the 4ºC refrigerator or from the -20°
freezer, warmed to room temperature and resuspended with sterile peptone-saline solution. Appropriate serial dilutions were made and duplicate potato agar plates were inoculated uniformly to quantitate the number of colony forming units/ml.
1 × 1011 CFU/ml of either Strain 19, 2308 or 2308 M106 in peptone-saline solution were inoculated into the 1 liter fermentation flask as described above. 8. Conditions and Times for Incubation
The fermentation flask was inoculated with at least 1 × 1011 CFU of B. abortus Strain 19, 2308 or 2308 M106 obtained by harvesting a 48-hour growth from a seed slope. Once inoculated, the fermentation flask was incubated at 37°C for 48 hours using the following rates for agitation and aeration. After 48 hours incubation, a sample was removed for examination and the brucellae were removed from the medium by centrifuging at 5000 x g.
Figure imgf000015_0001
9. Character and Amount of Growth
Examinations were carried out on the fermentation sample and the satisfactory results for B. abortus are as follows:
viable count 2.5-3 × 1011 per ml
pH 7.2-7.4
density (packed cell volume) 8-9%
purity 100% brucellae
dissociation none 10. Method of Killing
Harvested thick paste-like sediment of all B. abortus was placed in 50 ml polycarbonate Oakridge tubes and frozen at -20°C. The frozen suspension of bacteria were subsequently irradiated at a total dosage of 1.38 megarads using a 60Co industrial gamma radiation source. Verification of inactivation was confirmed by culture of 0.2 ml of the treated cultures on TSA in 5% carbon dioxide with incubation at 37ºC for 5 days.
C. HARVEST
1. Composition and Reaction of Media
The following recipe was used for B. abortus:
Bacto-dextrose 30.0g
peptone "M" 30.0g
Bacto-yeast extract 1 0.0g
sodium dihydrogen phosphates 9.0g
disodium hydrogen phosphate 3.3g
distilled water 1 liter
While mixing, the water was brought just to boiling and peptone "M" was added. The solution was allowed to simmer for 15 minutes, and then allowed to cool for 10 minutes.
While mixing, dextrose, yeast extract, sodium dihydrogen phosphate, and disodium hydrogen phosphate were added. The solution was cooled for about 30 minutes, the pH (about 6.4) was checked and the 800 ml of medium was filtered into the 1 liter fermentation flask. The hose was removed from the medium inlet port and the port was immediately covered with cotton saturated with 70% ethanol. The sterile cap was removed from the beaker and placed on the medium inlet port of the fermentation flask containing 10 ml of distilled water and 0.4 ml of anti-foam 60 silicone emulsion.
2. Minimum and Maximum Period of Time From Inoculation Until Harvest
Time from inoculation until harvest was 48 hours ± 2 hours for B. abortus.
3. Technique of Harvesting
Following fermentation, the medium containing B. abortus was immediately (i.e. no more than 5 minutes) harvested by centrifugation at 5000 x g in a refrigerated centrifuge at 4°C. The supernatant was aspirated from the sediment while collecting the supernatant in a trap filtration flask. 4. Specification for Acceptable Harvest Material
Examinations were carried out on the fermentation sample and the satisfactory results for B. abortus were as follows:
viable count 2.5-3 x 1011 per ml
pH 7.2-7.4
density 8-9%
purity 100% brucellae
dissociation none 5. Handling of Discarded Material
All supernatant and discarded material from B. abortus cultures were autoclaved for 15 minutes at 15 psi at 121 °C.
D. PREPARATION OF VACCINE AGAINST B. ABORTUS
1. Method of Inactivation
Refer to Method of Killing (see # 10 above) for details.
2. Composition of Adjuvant
Each individual 10-dose vial for cattle contained the following lyophilized adjuvant mixture:
1) 2.5 mg Monophosphoryl lipid A
2) 2.5 mg Trehalose dimycolate
3) 2.5 mg Cell Wall Skeleton
4) 1.0 ml Drakeol 6VR
5) 0.04 ml Monooleate (Tween 80)
6) 1200 mg Lecithin
3. Method and Degree of Concentration of Cell Envelopes
Cell envelopes from B. abortus Strain 2308 M106 were prepared as follows. Cultures of Brucella abortus strain S2308 M106 were fermenter grown in Trypticase soy broth to an OD550 of 106-133. The cells were harvested, rendered nonviable by irradiation with 1.38 Mrad of 60Co gamma radiation at 4°C, and frozen at -20 °C. The cells were then thawed and subjected to osmotic and sonic shock to rupture the cells and purified cell envelopes were collected by the method described by J.F. Lutkenhaus, J. Bacteriol.. 131:631-637 (1977), with the following modifications: 10 milliliter aliquots of thawed suspended cells were centrifuged at 12,000 rpm (10,000 x g) for 5 minutes at 4ºC to remove the cells from suspension. The resulting supernatant was then discarded. The pelleted cells were resuspended in 12 milliliters of Lutkenhaus buffer and subjected to 20,000 Hz sonic disruption for 6 consecutive periods of both 3 minutes at 300 watts and 2 minutes at 50 watts of power. During the sonication process, the suspension was held in an ice bath. The suspension was centrifuged at 12,000 rpm for 5 minutes to remove any unlysed cells and the resulting pellet was discarded. (Sowa, B.A., et al, Veterinary Microbiology. 27:351-369 (1991)). The supernatant from above was centrifuged at 30,000 rpm (100,000 x g) at 4°C for 45 minutes and the resulting supernatant was discarded. The pellets were resuspended in 1.5 milliliters of Lutkenhaus buffer by sonication at 20,000 Hz at 100 watts of power for 1-2 minutes. The process was repeated and the protein concentration of the resulting suspension was determined using the BCA protein assay kit available from The Pierce Chemical Company and comparing the readings to the mean of values obtained using controls of bovine serum albumin and ovalbumin standards.
The process yielded 6 to 9 milligrams of protein per milliliter (Sowa, B.A., et al, Veterinary Microbiology, 27:351-369 (1991)).
As a result of the unique nature of Brucella abortus, cell envelopes prepared as described above consist only of outer membrane-peptidoglycan complex (Sowa, et al., Vet. Microbio. 27:351-369, 1991). For the purpose of this invention, the terms cell envelopes and outer membrane-peptidoglycan (OM-PG) are used interchangeably.
4. Standardization and Determination of Amounts
Protein content of cell envelope preparations of B. abortus 2308 M106 was determined by the Pierce
Chemical Company bicinchoninic acid (BCA) protein assay (Smith, P.K. et al. Measurement of Protein Using Bicinchoninic Acid, Analytical Biochemistry, 150:76-85 1985).
5. Unit assembly
a. Assembly of Units to Make Serial
The adjuvant solution was homogenized with the cell envelopes such that 1.0 ml of the adjuvant solution contained the quantities for each immunogen as given in Table 1 (below), and 10 mis of the emulsion was dispensed into single 10 ml crimped, rubber stoppered vaccine vials. Each dose was 1 ml and each vial contained ten one ml doses. b. Other Information
The sterility of the water solution and adjuvant material was determined by inoculation of 0.2 ml of the respective solutions onto 2% bovine blood nutrient agar plates and brucella agar nutrient agar with 5% bovine serum supplement and incubating for at least 5 days at 37°C.
6. Volume of Fill for Each Vial
The volume of fill for each vial was 10 mis.
7. Method and Technique of Filling and Sealing
The 10 ml of adjuvant/immunogen was dispensed by a multiple dose dispensing syringe and lyophilized with sealing and crimping done under vacuum.
The 10 mis of adjuvant/immunogen was dispensed by multi-dose dispensing syringe under a laminar flow hood and crimped and sealed with a rubber stopper. 8. Amount of Antigenic Material per Dose
The reconstituted cell envelopes of B. abortus Strain 2308 M106 contained 1,200.0 μg per 1.0 ml.
E. TESTING
1. Potency
The immunogens were evaluated in cattle for their ability to induce significant protective immunity (p < 0.05) at 240 days post vaccination by challenge with pathogenic 1 × 107 CFU B. abortus S 2308 described as follows.
Randomization of treatment groups was done by the following manner. A total of 76 heifers were available for assignment to 3 treatment groups. Ear tag numbers were assigned to these heifers. Since the cattle were "worked through the pens" in a random manner, the ear tags were assigned sequentially as they are handled. A random number generator was used to assign the 76 cows to 3 intermediate groups. The 3 treatments were assigned numbers from 1 to 3 and assigned to groups using a random number table.
The random numbers were selected in the following manner:
a. A disinterested individual selected the row and column to start with using the random number tables in An Introduction to Statistical Methods and Data Analysis by Ott, pg 713, Table 7. b. The numbers (left to right) selected were: (53498, 18602 and 70659). Therefore treatment #5 was assigned to group #1 and treatment #3 was assigned to group #2 etc., until all treatments were assigned to a group.
Briefly, each heifer (at 130-200 days of gestation) was challenged by conjunctival instillation at 240 days post-vaccination with 107 CFU of standard USDA virulent B. abortus Strain 2308 and monitored until 420 days post-vaccination for: (1) abortion, (2) B. abortus culture of each fetus, placental membranes, milk and 50 tissues from necropsy of each dam, and (3) monthly serology pre- and post-vaccination and weekly serology post-challenge to include the card test, Rivanol test, complement fixation (CF) test, and rough and smooth enzyme-linked immunosorbent assay (ELISA).
Data derived from the experiments were analyzed for the treatment groups described in Example III. For purposes of evaluation of the effects of vaccination treatments on protective immunity, the individual cattle from treatment groups was classified as not protected or protected.
Not protected heifers were defined as B. abortus Strain 2308 culture positive. Differences between treatments were evaluated by Fisher's Exact Test for discrete variables i.e. abortion, isolation, and seroreactivity. EXAMPLE II
ASSESSMENT OF THE IN VITRO AND IN VIVO
BIOLOGIC STABILITY OF M106 TRANSPOSON MUTANT
OF BRUCELLA ABORTUS FOR USE AS LIVE VACCINES IN CATTLE
This example clearly demonstrates the stability of the O-polysaccharide deficient transposon mutant m106. Thus, this transposon mutant is stable and its O-polysaccharide antigen deficient characteristic does NOT revert back to a smooth strain. 1 . Introduction
The Brucellae are characterized by a number of phenotypic properties including colony type, antigenicity, virulence, growth rates, viability, resistance to antibiotics, and dye and salt sensitivity. Each of these characteristics has been found to vary individually but there is a high degree of association of changes in certain characteristics (Braun, W. Variation in the Genus Brucella. In Symposium on Brucellosis. AAAS,
Washington, p. 26-36). The genetic basis for this variation (if any) is not known. M. Moriera Jacob found species and type reversion in 64 isolates out of a collection of 300 (Moriera-Jacob, M. 1963. In vitro species (or type) transformation among strains of Brucella. Nature. 197:406). Out of 35 isolates of B. melitensis stored for one year, 12 reverted to B. intermedia. 1 to B. suis and 3 to B. strain AM (B. abortus of M-serotype). Frequent identification of atypical isolates both in the United States and Canada have compelled some investigators to call for re-classification (Ewalt, D.R. and L.B. Forbes. 1987. Atypical isolates of Brucella abortus from Canada and the United States characterized as dye sensitive with M antigen dominant. J. Clin. Microbiol. 25:698-701). Stability with regard to phenotypic variation is a relative term and depends upon the mechanism of variation. Variation may arise due to changes in growth conditions that alter gene expression. Such variation does not reflect true genotypic speciation. Taxonomic classification based on properties of this nature is fraught with difficulties as one tries to establish the properties which truly reflect species boundaries. This is especially true for the Brucella. die speciation and biotype analysis of which has depended on classification according to numerical analysis of phenotypic features. The phenotypic diversity of this group of organisms has lent itself to extensive analysis in an attempt to determine the taxonomic relationships. However, most researchers have concluded that the Brucella although generally divided into distinct forms nevertheless represent an almost infinite number of variants. Point mutations occur naturally at a rate of 1 × 10-6 per cell per generation and are easily revertible either at the primary site or by second site reversion. These also occur at a rate of 10-6. Deletions on the other hand do not revert at high frequency since the genetic information is lost. Reversion to wild type cannot occur without exchange of genetic information between cells or bacteriophage infection. Since exchange of this kind has not been documented for the Brucellae one may consider deletion mutants to be stable. In the case of transposon mutagenesis which occurs at a frequency of 10-2 to 10-3 reversion is observed at a well established level in the homologous system (106 to 10-10 for wild type Tn5 in E. coli depending on the site of insertion). However, when introduced into a heterologous background, i.e., E. coli transposons introduced into Brucella abortus, it is difficult to predict the insertion and reversion frequency (Kleckner, N. 1981. Transposable elements in prokaryotes. Ann. Rev. Genet. 15: 341-404). Stability must therefore be determined empirically. A derivative of wild type Tn5 (Tn5 lac Z) was used in these experiments and has approximately 5% the transposition rate of wild type Tn5. The reversion rate would be expected to be correspondingly lower (5 × 10-8 to 5 × 1012).
2. Materials and General Methods
Three pregnant goats, #1 , #2, #1985 were each vaccinated with 1 × 109 cells/ml of S19 vaccine
(Positive Control), S2308 M106:Tn5 lacZ, and PBS (Negative Control) respectively.
Every week, the following samples were collected: swabs of faeces, urine, saliva, tears, and blood. The collection of samples was carried out for 22 weeks. Swabs were streaked in triplicate on Farrell's media plates supplemented with 100 IU/ml nystatin and 3 μm/ml cyclohexamide.
Blood sera were filtered through 0.45 μm and 0.22 μm filters consecutively, to decontaminate the sera. Blood sera were streaked on modified Farrell's media plates. 3. Results from Swab Analyses
a. GOAT #1-S19 vaccine- Positive Control
B. abortus was not isolated from swabs of faeces, urine, saliva, tears, or blood. b. GOAT #2-S2308::Tn5 lacZ (m106)
B. abortus was not isolated from swabs of faeces, urine, saliva, tears or blood. c. GOAT #1985-Negative control
No B. abortus were isolated from swabs of faeces, urine, saliva, tears or blood. 4. Results from Necropsy Samples
Eight weeks post vaccination, Goat #1 parturated. Both mother and kid were necropsied. Twenty two weeks post vaccination, Goat #2, and #1985 had not conceived. Necropsy was carried out on both goats.
Gram-Stain and biotype analysis of colonies picked from all Farrell's plates were negative for Brucella so.
No Brucella isolated from any tissue samples examined. 5. Serology Results
Goat #2, vaccinated with S2308::Tn5 lacZ m106, never developed antibodies against O-polysaccharide and was consistently brucella negative by card, rivanol, and complement fixation tests.
Goat Number 1 2 1985
Bacteriology
(weeks) 0 - - -
1 - - -
2 - - -
3 - - -
4 - - -
5 - - -
20 * - -
*sacrificed at week 8
Goat Number 1 2 1985
Card test 0 - - -
1 + - -
2 + - -
3 + - -
4 + - -
5 - - -
20 * - - *sacrificed at week 8
Goat Number 1 2 1985
Rivanol 0 - - -
1 400 - -
2 400 - -
3 400 - -
4 400 - -
5 200 - -
6 100 - -
7 100 - -
8 200 - -
20 * - -
*sacrificed at week 8
Goat Number 1 2 1985
Complement 0 - - - fixation 1 1+40 - -
2 2+20 - -
3 3+20 - -
4 3+20 - -
5 2+20 - -
6 2+10 - -
7 1+10 - -
8 - - -
20 * - -
*sacrificed at week 8
Goat Number 1 2 1985
ELISA 0 0. 140 0.139 0.209
1 0. 726 0.179 0.207
2 1. 28 0.168 0.370
3 over 0.156 0.420
4 over 0.124 0.374
5 over 0.164 0.286
6 over 0.134 0.278
7 over 0.210 0.254
8 1. 157 0.137 0.272
9 * 0.140 0.150
10 * 0.102 0.164
11 * 0.086 0.180
12 * 0.199 ND
13 * 0.198 0.347
14 * 0.215 0.298
15 * 0.211 0.289
16 * 0.209 0.275
17 * 0.140 0.287
18 * 0.154 0.275
19 * 0.193 0.331
20 * 0.138 0.279
*sacrificed at week 8
6. Conclusions
Goats vaccinated with 1 × 109 cfu of transposon mutant S2308 M106::Tn5 had no organisms of the original phenotype ( Kmrlac+) recultured at any time post-exposure and no anti-O antibody was detected. By these criterion the results indicate that smooth organisms were undetectable either directly or indirectly. The reversion rate of m106 is therefore less than 3 × 109 revertants/cfu. Thus, it is expected that reversion to smooth phenotype would not be observed under the conditions used to grow the organism and to vaccinate cattle, and for practical purposes the mutant may be considered stable.
The stability of these KmrlacZ+ strains in the absence of selection pressure was examined. Ten independent Kmr of m106 transductants were streaked on Brucella agar plates without kanamycin. Single colonies from these plates were then grown in liquid shaker culture also in the absence of kanamycin at 37°C for 30 generations (3-4 generations per liquid culture which was passaged 10 times). The cultures were plated on brucella agar and 100-500 colonies were replica plated onto Brucella agar. All colonies grew on both sets of plates. Thus kanamycin resistance was stable for at least 50 generations (20 generations from a single colony, 30 to 40 generations in liquid culture).
7. Summary
Transposon mutant m106 was found to be stable in that it does not revert to the smooth, O polysaccharide containing B. abortus strain. Transposon mutant m106 was not maintained in or excreted by goats. This mutant did not stimulate anti-LPS antibodies which could confuse diagnosis.
Transposon mutant m106 was found to be stable in that it did not revert to smooth, O polysaccharide containing B. abortus strain as evidenced by:
1) the lack of in vivo seroconversion in the goat experiment;
2) lack of survivability in goat tissues;
3) lack of detection of O polysaccharide by O polysaccharide specific monoclonal antibody when grown in liquid medium or solid medium; and
4) failure to revert even when passaged repeatedly in vitro, which favors spontaneous transposon excision.
EXAMPLE III SUMMARY OF STUDIES OF CELL ENVELOPE SUB-UNIT
(OUTER MEMBRANE PEPTIDOGLYCAN) VACCINES
AGAINST BOVINE BRUCELLOSIS
USING THE METHODS DESCRIBED ABOVE 1. Specific Aims Designed for the Evaluation of Killed Sub-Unit (Outer Membrane Peptidoglycan)
Vaccines Against Boyine Brucellosis
The purpose of developing and evaluating these killed sub-unit vaccine preparations against bovine brucellosis was to produce a safe and protective vaccine that:
i) does not stimulate antibodies cross-reactive with existing USDA standard serodiagnostic assays;
ii) is not sex- or age-restricted, and;
iii) is not infectious for man or animals, thereby eliminating undesirable side-effects of the current Strain 19 vaccine. 2. Test of Product Efficacy for Killed Sub-Unit (Outer Membrane Peotidoelvcan) Vaccines
Against Bovine Brucellosis
Brucella abortus outer membrane peptidoglycan (OM-PG, Group 3) sub-unit vaccine preparations prepared as described above were compared to adjuvant alone (negative control, Group 1) and Strain 19 (positive control, Group 2) treatment groups of pregnant heifers in an approved statistically valid protocol as given in Table 1 below.
Figure imgf000025_0001
All cows were vaccinated on Week 0 (and Week 8 except for Strain 19 Group) and only pregnant cows were challenged on Week 37 with USD A standard virulent Brucella abortus S2308. The schedule of experimental procedures are as follows:
Blood samples for serum were collected from all cattle on Weeks -37, -27, -16 pre-vaccination, 0, 2, 4, 6, 8, 10, 13, 17, 21, 26, 30, 35, 37, 40, 41, 45, 47, 49, 51, 53, 55, and 57 post-vaccination. Cattle were injected with each treatment as given in Table 1 above (Group 1 - adjuvant alone on Weeks 0 & 8, Group 2 - Strain 19 only on Week 0, and Group 3 - adjuvant plus m106 OM-PG on Weeks 0 and 8). All cattle were estrus synchronized with Synchromate B (Elanco) and bred naturally from Week 8 through Week 17 and challenged with 0.81 × 107 CFU virulent Strain 2308 at mid-gestation on Week 37 post-vaccination. 3. Results Obtained from the Evaluation of Killed Sub-Unit (Outer Membrane Peptidoglycan)
Vaccines Against Bovine Brucellosis
a. General Comments
1). Detailed Supporting Data Document Not Attached Herein
Supporting data from all procedures, for all individual animals, for all treatment groups is available upon request.
2). Comparative Data For Group 1 - Adjuvant Negative Control. Group 2 - Strain 19
Positive Control, and Group 3 M106 OM-PG
Results from treatment Group 1 - Adjuvant = "RADJ" (negative control). Group 2 - Strain 19 =
"S19" (positive control), and Group 3 - M106 OM-PG = "TN12x2" (derived from a transposon mutant of
Brucella abortus Strain 2308) will be presented in this Example (see Table 28) below for statistical analysis). b. Antibody Responses to Vaccination and Challenge
1. Methods Employed for this Study
The serological data obtained for each test is scored from "0" to "4" (see Table 2 for scoring of serologic results). Serologic results from Week 0 through Week +37 Post-Vaccination are graphed in the Tables 4 - 18. Challenge with 0.81 × 107 cfu Brucella abortus S2308 occurred in Week +37. Abbreviations used in these Tables are as follows:
⌻ VWK= Week pre- (-) or post- (+) vaccination;
⌻ GPID= treatment group, i.e "RADJ" = Adjuvant Negative Control; "S19" = Strain 19 Positive Control; "TN12x2" = cell envelopes isolated from transposon mutant M106;
⌻ UCF= complement fixation;
⌻ UCD= card test;
⌻ ELS= Smooth indirect Brucella ELISA;
⌻ URV= Rivanol test; and
⌻ ELR= Rough indirect Brucella ELISA.
Complete individual animal data, by treatment group and sequential experimental animal number are available upon request from Week -37 through Week +57.
Figure imgf000027_0001
Tables 3-7 present data obtained from "adjuvant only" (negative control, "RADJ," experimental group 1). The data are presented for each test (i.e. "ELR" is the rough indirect Brucella ELISA). Weeks 0,
2, 4, 6, 8, 10, 13, 17, 21, 26, 30, 35 and 37 are presented in these tables. Numbers underneath the scores are the number of animals studied (e.g. "25") and the percentage of the total is presented in the parenthesis ("(96.2)").
TABLE 3
TREAT: RADJ TEST: ELR
Week 0 2 4 Total
0 25 (96.2) 1 (3.9) 0 (0.0) 26
2 21 (80.8) 4 (15.4) 1 (3.9) 26
4 16 (61.5) 8 (30.8) 2 (7.7) 26
6 19 (73.1) 4 (15.4) 3 (11.5) 26
8 25 (96.2) 0 (0.0) 1 (3.9) 26
10 26 (100.0) 0 (0.0) 0 (0.0) 26
13 26 (100.0) 0 (0.0) 0 (0.0) 26
17 25 (96.2) 1 (3.9) 0 (0.0) 26
21 25 (96.2) 1 (3.9) 0 (0.0) 26
26 26 (100.0) 0 (0.0) 0 (0.0) 26
30 26 (100.0) 0 (0.0) 0 (0.0) 26
35 24 (100.0) 0 (0.0) 0 (0.0) 24
37 23 (95.8) 1 (4.2) 0 (0.0) 24 TABLE 4
TREAT: RADJ TEST: ELS
Week 0 Total
0 26 (100.0) 26
2 26 (100.0) 26
4 26 (100.0 26
6 26 (100.0) 26
8 26 (100.0) 26
10 26 (100.0) 26
13 26 (100.0) 26
17 26 (100.0) 26
21 26 (100.0) 26
26 26 (100.0) 26
30 26 (100.0) 26
35 24 (100.0) 24
37 24 (100.0) 24
TABLE 5
TREAT: RADJ TEST: UCD
Week 0 Total
0 26 (100.0) 26
2 26 (100.0) 26
4 26 (100.0) 26
6 26 (100.0) 26
8 26 (100.0) 26
10 26 (100.0) 26
13 26 (100.0) 26
17 26 (100.0) 26
21 26 (100.0) 26
26 26 (100.0) 26
30 26 (100.0) 26
35 24 (100.0) 24
37 24 (100.0) 24 TABLE 6
TREAT: RADJ TEST: UCF
Week 0 Total
0 26 (100.0) 26
2 26 (100.0) 26
4 26 (100.0) 26
6 26 (100.0) 26
8 26 (100.0) 26
10 26 (100.0) 26
13 26 (100.0) 26
17 24 (100.0) 24
21 26 (100.0) 26
26 26 (100.0) 26
30 26 (100.0) 26
35 24 (100.0) 24
37 24 (100.0) 24
TABLE 7
TREAT: RADJ TEST: URV
Week 0 Total
0 26 (100.0) 26
2 26 (100.0) 26
4 26 (100.0) 26
6 26 (100.0) 26
8 26 (100.0) 26
10 26 (100.0) 26
13 26 (100.0) 26
17 26 (100.0) 26
21 26 (100.0) 26
26 26 (100.0) 26
30 26 (100.0) 26
35 24 (100.0) 24
37 24 (100.0) 24
Tables 8-12 present data obtained from "Strain 19" as the immunogen (positive control, "S19," experimental group 2). The data are presented for each test (i.e. "ELR" is the rough indirect Brucella
ELISA). One dose of 3.4 × 108 colony forming units was given on day 0 (see Table 1 above). Weeks 0, 2, 4, 6, 8, 10, 13, 17, 21, 26, 30, 35 and 37 are presented in these tables. Numbers underneath the scores are the number of animals studied (e.g. "25") and the percentage of the total is presented in the parenthesis ("(96.2)"). TABLE 8
TREAT: S19 TEST: ELR
Week 0 2 4 Total
0 24 (96.0) 1 (4.0) 0 (0.0) 25
2 17 (68.0) 8 (32.0) 0 (0.0) 25
4 8 (32.0) 11 (44.0) 6 (24.0) 25
6 14 (56.0) 6 (24.0) 5 (20.0) 25
8 21 (84.0) 4 (16.0) 0 (0.0) 25
10 22 (88.0) 3 (12.0) 0 (0.0) 25
13 25 (100.0) 0 (0.0) 0 (0.0) 25
17 25 (100.0) 0 (0.0) 0 (0.0) 25
21 20 (80.0) 5 (20.0) 0 (0.0) 25
26 24 (96.0) 1 (4.0) 0 (0.0) 25
30 22 (88.0) 2 (8.0) 1 (4.0) 25
35 21 (100.0) 0 (0.0) 0 (0.0) 21
37 20 (95.2) 0 (0.0) 1 (4.8) 21
TABLE 9
TREAT: S19 TEST: ELS
Week 0 2 4 Total
0 25 (100.0) 0 (0.0) 0 (0.0) 25
2 12 (48.0) 13 (52.0) 0 (0.0) 25
4 2 (8.0) 6 (24.0) 17 (68.0) 25
6 4 (16.0) 10 (40.0) 11 (44.0) 25
8 8 (32.0) 14 (56.0) 3 (12.0) 25
10 9 (36.0) 12 (48.0) 4 (16.0) 25
13 16 (64.0) 8 (32.0) 1 (4.0) 25
17 24 (96.0) 1 (4.0) 0 (0.0) 25
21 25 (100.0) 0 (00.0) 0 (0.0) 25
26 25 (100.0) 0 (0.0) 0 (0.0) 25
30 23 (92.0) 2 (8.0) 0 (0.0) 25
35 21 (100.0) 0 (0.0) 0 (0.0) 21
37 21 (100.0) 0 (0.0) 0 (0.0) 21 TABLE 10
TREAT: S19 TEST: UCD
Week 0 4 Total
0 25 (100.0) 0 (0.0) 25
2 0 (0.0) 25 (100.0) 25
4 1 (4.0) 24 (96.0) 25
6 1 (4.0) 24 (96.0) 25
8 5 (20.0) 20 (80.0) 25
10 4 (16.0) 21 (84.0) 25
13 14 (56.0) 11 (44.0) 25
17 21 (84.0) 4 (16.0) 25
21 23 (92.0) 2 (8.0) 25
26 25 (100.0) 0 (0.0) 25
30 24 (96.0) 1 (4.0) 25
35 21 (100.0) 0 (0.0) 21
37 20 (95.2) 1 (4.8) 21
TABLE 11
TREAT: S19 TEST: UCF
Week 0 1 2 3 4 Total
0 25 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 25
2 0 (0.0) 1 (4.2) 3 (12.5) 2 (8.3) 18 (75.0) 25
4 2 (8.0) 1 (4.00) 4 (16.0) 11 (44.0) 7 (28.0) 25
6 5 (20.0) 8 (32.0) 11 (44.0) 1 (4.0) 0 (0.0) 25
8 20 (80.0) 3 (12.0) 2 (8.0) 0 (0.0) 0 (0.0) 25
10 22 (88.0) 3 (12.0) 0 (0.0) 0 (0.0) 9 (0.0) 25
13 25 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 25
17 24 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 25
21 24 (96.00) 1 (4.0) 0 (0.0) 0 (0.0) 0 (0.0) 25
26 25 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 25
30 25 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 25
35 21 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 21
37 21 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 21 TABLE 12
TREAT: S19 TEST: URV
Week 0 1 2 3 4 Total
0 25 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 25
2 0 (0.0) 2 (8.0) 6 (24.0) 1 (4.0) 16 (64.0) 25
4 2 (8.00) 2 (8.00) 5 (20.0) 5 (20.0) 11 (44.0) 25
6 2 (8.00) 4 (16.0) 10 (40.0) 5 (20.0) 4 (16.0) 25
8 7 (28.0) 7 (28.0) 7 (28.0) 4 (16.0) 0 (0.0) 25
10 10 (40.0) 10 (40.0) 4 (16.0) 1 (4.0) 0 (0.0) 25
13 20 (80.0) 3 (12.0) 2 (8.0) 0 (0.0) 0 (0.0) 25
17 25 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 25
21 25 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 25
26 25 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 25
30 25 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 25
35 21 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 21
37 21 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 21 Tables 13-17 present data obtained from "TN12x2" as the immunogen (cell envelopes isolated from transposon mutant M106, "TN12x2," experimental group 3). The data are scored and presented for each test (i.e. "ELR" is the rough indirect Brucella ELISA). One dose of 1,200 μg was given on day 0 and another dose of 1,200 μg was given on day 57 for a total of 2,400 μg (see Table 1 above). Weeks 0, 2, 4, 6, 8, 10, 13, 17, 21, 26, 30, 35 and 37 are presented in these tables. Numbers underneath the scores are the number of animals studied (e.g. "25") and the percentage of the total is presented in the parenthesis ("(96.2)").
TABLE 13
TREAT: TN12x2 TEST: ELR
Week 0 2 4 Total
0 20 (80.0) 4 (16.0) 1 (4.0) 25
2 1 (4.0) 15 (60.0) 9 (36.0) 25
4 2 (8.0) 7 (28.0) 16 (64.0) 25
6 0 (0.0) 7 (28.0) 18 (72.0) 25
8 4 (16.0) 6 (24.0) 15 (60.0) 25
10 0 (0.0) 1 (4.0) 24 (96.0) 25
13 0 (0.0) 0 (0.0) 24 (100.0) 26
17 0 (0.0) 1 (4.2) 23 (95.9) 24
21 0 (0.0) 4 (16.7) 20 (83.3) 24
26 1 (4.35) 6 (26.1) 16 (69.6) 23
30 2 (8.70) 4 (17.4) 17 (73.9) 23
35 4 (25.0) 5 (31.3) 7 (43.8) 16
37 1 (6.3) 5 (31.3) 10 (62.5) 16
TABLE 14
TREAT: TN12X2 TEST: ELS
Week 0 2 4 Total
0 25 (100.0) 0 (0.0) 0 (00) 25
2 22 (88.0) 2 (8.0) 1 (4.0) 25
4 23 (92.0) 2 (8.0) 0 (0.0) 25
6 25 (100.0) 0 (0.0) 0 (0.0) 25
8 25 (100.0) 0 (0.0) 0 (0.0) 25
10 20 (80.0) 3 (12.0) 2 (8.0) 25
13 19 (79.2) 4 (16.7) 1 (4.2) 24
17 23 (95.8) 0 (0.0) 1 (4.2) 24
21 23 (95.8) 1 (4.2) 0 (0.0) 24
26 22 (95.7) 1 (4.4) 0 (0.0) 23
30 22 (95.7) 1 (4.4) 0 (0.0) 23
35 16 (100.0) 0 (0.0) 0 (0.0) 16
37 16 (100.0) 0 (0.0) 0 (0.0) 16 TABLE 15
TREAT: TN12X2 TEST: UCD
Week 0 4 Total
0 25 (100.0) 0 (0.0) 25
2 25 (100.0) 0 (0.0) 25
4 25 (100.0) 0 (0.0) 25
6 25 (100.0) 0 (0.0) 25
8 25 (100.0) 0 (0.0) 25
10 24 (96.0) 1 (4.0) 25
13 24 (100.0) 0 (0.0) 24
17 24 (100.0) 0 (0.0) 24
21 24 (100.0) 0 (0.0) 24
26 23 (100.0) 0 (0.0) 23
30 23 (100.0) 0 (0.0) 23
35 16 (100.0) 0 (0.0) 16
37 16 (100.0) 0 (0.0) 16
TABLE 16
TREAT: TN12X2 TEST: UCF
Week 0 1 2 3 Total
0 25 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 25
2 25 (100.0 0 (0.0) 0 (0.0) 0 (0.0) 25
4 25 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 25
6 25 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 25
8 25 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 25
10 23 (92.0) 2 (8.0) 0 (0.0) 0 (0.0) 25
13 24 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 24
17 22 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 22
21 24 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 24
26 22 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 22
30 23 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 23
35 16 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 16
37 16 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 16 TABLE 17
TREAT: TN12X2 TEST: URV
Week 0 Total
0 25 (100. 0) 25
2 25 (100.0) 25
4 25 (100.0) 25
6 25 (100.0) 25
8 25 (100.0) 25
10 25 (100.0) 25
13 24 (100 .0) 24
17 24 (100 .0) 24
21 24 (100 .0) 24
26 23 (100 .0) 23
30 23 (100 .0) 23
35 16 (100.0) 16
37 16 (100 .0) 16 2. Results of Antibody Responses
With the exception of one spurious card test and two complement fixation test results in Week 10, in treatment Group 3 (vaccinated with M106 OM-PG 120Oμg x 2), no serologic responses were detected by the USDA standard card (Table 15), complement fixation (Table 16), or Rivanol (Table 17) diagnostic tests for brucellosis up to Week 37 (day of challenge) post-vaccination in the heifers vaccinated with the M106 OM-PG B. abortus vaccine. This demonstrated the virtual absence of cross-reactive antibodies which confuse standard
USDA serodiagnostic tests. Good serologic responses predictive of protection as determined by the rough Brucella ELISA test occurred in all of the Group 3 sub-unit rough M106 OM-PG B. abortus vaccinated heifers (Table 13 ). Additionally, Western Blot analyses using antibodies generated against the rough OM-PG sub-unit from B. abortus vaccinated cattle, corroborated the data obtained from the rough indirect Brucella ELISA test (serologic responses were observed in all of the Group 3 sub-unit rough M106 OM-PG B. abortus vaccinated heifers; data not given but available upon request). In contrast to Group 3, Group 2 heifers vaccinated with Strain 19 had very high percentages of false positive serologic responses detected by the card (Table 10), complement fixation (Table 11) and rivanol (Table 12) tests beginning Week +2 post-vaccination. This group retained high diagnostic antibody titers through Week +37 post-vaccination. Indeed, one cow (number 1269) was persistently infected with Strain 19, thus producing sustained high levels of antibodies detected by standard USDA serodiagnostic tests. c. Cell Mediated Immune Responses
The cell mediated immune responses, as determined by peripheral blood lymphocyte transformation assays, are presented in Tables 18 and 19.
The results indicated that Group 3 heifers vaccinated with sub-unit Ml 06 OM-PG B. abortus preparations responded as well as, if not better, than heifers vaccinated with Strain 19 when given two injections at a 2 month interval. The M106 OM-PG 1200μg x 2 vaccination regimen stimulated the greatest overall cell mediated immune response.
The data presented in Table 18 represent the in vitro lymphocyte responses of cattle to OM-PG antigen. These data clearly demonstrate that cattle vaccinated with strain M106 OM-PG had lymphocytes responsive to antigens contained in the OM-PG preparations. Significantly higher numbers of OM-PG vaccinated cows responded to OM-PG antigens than did cows given adjuvant alone or strain 19 vaccination. RB-51 is an O polysaccharide deficient mutant strain of B. abortus. Schurig et al. Biological properties of RB51; a stable rough strain of Brucella abortus. Vet. Microbiol.. 28:171-188. The data presented in Table 19 represent the in vitro lymphocyte responses of the same cattle to whole cell antigens of B. abortus strain 2308. These data also demonstrate significant numbers of responsive cattle in the groups that received of M106 OM-PG and in the group vaccinated with strain 19. For in vitro responses to these antigens, vaccination with strain 19 was statistically equivalent to vaccination with OM-PG.
Table 18
FREQUENCY OF RESPONSES TO B. ABORTUS STRAIN RB51 OM-PG IN IMMUNIZED CATTLE
Immunogen Number of Positive Responses X2 No.
(Percent) (P) of Cows
(Assays)
None 1 2 3 4 versus versus
Adj. Strain 19
1. Adjuvant 21 2 0 0 0 na na 23
(91) (9) (0.0) (0.0) (0.0) (84)
2. Strain 19 9 9 2 5 0 15.2* na 24
(48) (33) (8) (21) (0.0) (0.002) (83)
3. M106 OM-PG 1 6 8 6 2 36.2* 12.4 23 (2 × 1,200μg) (4) (26) (35) (26) (9) (<0.001) (0.015) (87)
Total 31 17 10 11 2 70
TABLE 19
FREQUENCY OF RESPONSES TO B. ABORTUS STRAIN 2308 IN IMMUNIZED CATTLE
Immunogen Number of Positive Responses X2 No.
(Percent) (P) of Cows
(Assays)
None 1 2 3 4 versus versus
Adj. Strain 19
1. Adjuvant 11 8 4 0 0 na na 23
(48) (35) (17) (0) (0) (84)
2. Strain 19 1 7 6 9 1 18.9* na 24
(4) (29) (25) (38) (4) (<0.001) (83)
3. M106 OM-PG 0 6 7 6 4 22.0* 3.7 23 (2 × 1,200μg) (0) (26) (30) (26) (17) (<0.001) (0.448) (87)
Total 12 21 17 15 5 70
The following conclusions are drawn from this cell mediated immune response data: (1)
Lymphocyte responsiveness can be induced by OM-PG of rough strains of B. abortus and (2) The apparent specificity of lymphocytes responding to immunization with OM-PG differs from those responding to strain 19 vaccination.
A summary of the lymphocyte reactivities is presented below.
Figure imgf000038_0001
d. Challenge & Bacteriologic Results
All pregnant cows were challenged with 0.81 × 107 cfu Brucella abortus S2308 in Week 37 and tissues and mammary secretions were collected at parturition and 30 days post-parturition if the first bacteriologic culture attempt was negative.
The results of bacteriologic cultures for recovery of Brucella abortus from the 11 composite tissues collected each cow and her corresponding fetus are given in Tables 20 - 27.
Data obtained from cows immunized with experimental groups 1 - 3 arc presented in Tables 20 - 23. Data obtained from matching calfs from each cow are presented in Tables 24 - 27. Corresponding numbers followed by "A" represent the matching calf to the cow. Corresponding cow and calf tables are presented below
Conclusions from these challenge and bacteriologic studies are presented in Table 28. For example, table number 20 (cow) corresponds with table number 24 (calf), table 21 corresponds with table 25, table 22 corresponds with table 26 and table 23 corresponds with table 27.
The following abbreviations are used in these Tables: Gp. No.= experimental group number; Rec. Swab.= rectal swab; Med. LN= mediastinal lymph node; Lung= lung; Ab. Swab= abomasal swab;
Abom.= abomasum; Placenta= placenta; Total= sum of each tissue; Dist.= number of culture positive tissues; Inf. Index= sum x total number of culture positive tissues; Average= sum divided by total number of culture positive tissues; Live Birth = calf that breathed (i.e. lungs were aerated).
Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000041_0001
Figure imgf000042_0001
Figure imgf000043_0001
Figure imgf000044_0001
Figure imgf000045_0001
Figure imgf000046_0001
e. Protection Against Infection & Fetal Death
Using the data from the bacteriologic cultures and fetal death data, the results of the M106 OM-PG induced protection against infection and fetal death are given in the attached Table 28. The results were obtained when M106 OM-PG was injected at week 0 into heifers. These pregnant heifers (days of gestation at challenge = day 125 to day 185) were experimentally challenged on Week 37 Post- Vaccination with the USDA standard inoculum of 0.81 × 107 cfu B. abortus S2308.
The results from this study demonstrate that M106 OM-PG induced statistically significant (p< 0.001) protection (87.5%) against fetal death, i.e. more living calves, as compared to non-vaccinated controls (45.8%). M106 OM-PG also stimulated more protective immunity against fetal death than did Strain 19 (80%), although not statistically significant. Neither Strain 19 (p <0.057) nor M106 OM-PG (p <0.508) produced statistically significant protection against infection as compared to non-vaccinated controls which reflects the severity of the experimental challenge. Additionally no statistical differences occurred when S19 was compared to M106 OM-PG with regard to protection against infection.
Figure imgf000047_0001
§ Without regard to fetal age at parturition.
None of the vaccines, including Strain 19, induced statistically significant protection against infection. However, both Group 2 (Strain 19) and Group 3 (M106 OM-PG 1200 μg x 2) produced statistically significant protection against fetal death as compared to the Adjuvant negative control Group 1. No statistically significant differences were observed between the Strain 19 group and the M106 OM-PG vaccinated group.
M106 OM-PG vaccine, like Strain 19, greatly reduced the number of B. abortus reaching the fetus as compared to the Adjuvant negative control Group 1 (data not shown). This reduction significantly increased fetal survivability while permitting an increasing number of B. abortus to persist in the cow (data not shown). These data indicate that M106 OM-PG vaccinated cows would produce significantly more viable calves and shed fewer B. abortus into the environment. f. Safety and Toxicology Results
Intramuscular injections of the sub-unit rough (m106) cell envelope OM-PG B. abortus vaccine into cattle produced detectable granulomas at 60 days after the first injection, as well as for 30 days after the second injection. Of interest, all granulomas spontaneously resolved 60 days after the second injection. These data are presented in Tables 29 and 30.
Figure imgf000049_0001
Figure imgf000049_0002
g. Formulation and Pharmacy Results
The proportions and techniques for combining the purified rough OM-PG of B. abortus with the low oil adjuvant have been established using an USDA approved adjuvant formulation produced by Ribi Immunochem, Inc. under Good Laboratory Practices regulations. See above for details. 4. Summary of the Evaluation of Killed Sub-Unit (Outer Membrane Peotidoglycan)
Vaccines Against Bovine Brucellosis
The killed sub-unit rough M106 OM-PG B. abortus vaccine induced statistically significant
(p < 0.001) protection against fetal death, which was not significantly different from USDA Strain 19 vaccination (i.e. statistically equivalent).
The killed sub-unit OM-PG envelope vaccine did not stimulate significant cross reactivity on USDA card, Rivanol, or complement fixation diagnostic tests. This is in direct contrast to long term high levels of cross-reactive antibodies being stimulated by the standard USDA Strain 19 vaccine.
Conclusions Drawn from the Evaluation of Killed Sub-Unit (Outer Membrane Peptidoglycan) Vaccines Against Bovine Brucellosis
The killed sub-unit rough M106 OM-PG B. abortus vaccine, like Strain 19, induced protection against fetal death for up to 37 weeks post-vaccination when inoculated was a two dose series at a 57 day interval. This protective immunity was obtained without stimulating cross reactive antibodies in standard
USDA diagnostic assays.
Importantly, the use of M106 OM-PG B. abortus vaccine potentially means that any serologic responses detected by the current standard USDA serodiagnostic tests would indicate field strain infection, thus permitting protection and differential diagnosis.
EXAMPLE IV
INDUCED PROTECTIVE IMMUNITY WITH LIVE B. ABORTUS TRANSPOSON MUTANT M106
In order to evaluate the protection induced by live M106 against brucellosis, a dose of 0.6 × 1010 .CFU of M106 was injected subcutaneously to vaccinate 25 cows as compared to 25 Strain 19 vaccinated positive control cows and 25 non-vaccinated negative control cows on October 8, 1991. Serum samples were collected each 2 weeks for 6 weeks before vaccination and each 2 weeks since then to evaluate the immune response. These cows were estrus synchronized and bred naturally in preparation for virulent challenge with 1 × 107 CFU Strain 2308 on Week 37 post-vaccination. None of the cattle have developed brucellosis but they have demonstrated good antibody responses as detected by the rough indirect ELISA procedure.
* * *
From the above, it will be clear to one skilled in the art that several different approaches can be used to develop or to reach the same end result, namely a vaccine which provides protective immunity against Brucella abortus, yet provides a means for differentiating between field strain infected and vaccinated cattle.

Claims

CLAIMS:
1. A vaccine for providing protective immunity to a host animal against pathogenic Brucella abortus comprising cell envelopes isolated from an O polysaccharide antigen deficient, stable transposon mutant of B. abortus, in an amount sufficient to induce protective immunity, together with a suitable carrier, wherein said cell envelopes contain intrinsic antigens of B. abortus except O polysaccharide antigen.
2. The vaccine of claim 1 wherein said amount of cell envelopes ranges from about 400 μg to about 4000 μg.
3. The vaccine of claim 1 further comprising a suitable adjuvant consisting essentially of 0.25 milligrams monophosphoryl lipid A, 0.25 milligrams Mycobacterium spp. cell wall skeleton, 0.25 milligrams of trehalose dimycolate, 120 milligrams of lecithin, 0.1 milliliters Drakeol 6VR, and 0.004 milliliters of Tween 80.
4. The vaccine of claim 1 wherein said mutant is B. abortus 2308 m106 R::Tn5lacZ having ATCC
Accession No. 67912.
5. A vaccine for providing protective immunity to a host animal against pathogenic Brucella abortus comprising cell envelopes isolated from an O polysaccharide antigen deficient, stable transposon mutant of B. abortus, in an amount ranging from about 400 μg to about 4000 μg, together with a suitable carrier, wherein cell envelopes contain intrinsic antigens of B. abortus except O polysaccharide antigen, wherein said stable transposon mutant is killed by exposure to a sufficient dose of 60Cobalt radiation at 4° C to render said stable transposon mutant nonviable, wherein cell envelopes are isolated from said killed transposon mutants and said vaccine further comprising an adjuvant consisting essentially of 0.25 milligrams monophosphoryl lipid A, 0.25 milligrams Mycobacterium spp. cell wall skeleton, 0.25 milligrams of trehalose dimycolate, 120 milligrams of lecithin, 0.1 milliliters Drakeol 6VR, and 0.004 milliliters of Tween 80.
6. Cell envelopes isolated from an O polysaccharide antigen deficient, stable transposon mutant of B. abortus, wherein said cell envelopes contain intrinsic antigens of B. abortus except O polysaccharide antigen.
7. The cell envelopes of claim 6 wherein said cell envelopes are isolated from transposon mutant B. abortus 2308 m106 R::Tn5lacZ having ATCC Accession No. 67912.
8. A vaccine for providing protective immunity in a host animal against pathogenic Brucella abortus comprising an O polysaccharide antigen deficient, stable transposon mutant of B. abortus, in an amount sufficient to induce protective immunity, wherein said transposon mutant contains intrinsic antigens of B. abortus except O polysaccharide antigen.
9. The vaccine of claim 8 wherein said amount of stable transposon mutant ranges from about 109 to about 1011 colony forming units.
10. The vaccine of claim 8 wherein said stable transposon mutant is B. abortus 2308 m106 R::Tn5lacZ having ATCC Accession No. 67912.
11. A vaccine for providing protective immunity to a host animal against pathogenic Brucella abortus comprising an O polysaccharide antigen deficient, stable transposon mutant of B. abortus, in an amount ranging from about 109 to about 1011 colony forming units.
12. An O polysaccharide antigen deficient, stable transposon mutant of Brucella abortus, wherein said transposon mutant contains intrinsic antigens of B. abortus except O polysaccharide antigen.
13. The transposon mutant of claim 13 wherein said mutant is B. abortus 2308 m106 R::Tn5lacZ having ATCC Accession No. 67912.
14. The transposon mutant of claim 8 wherein said mutant is attenuated.
PCT/US1993/001681 1992-02-25 1993-02-25 Improved vaccin against brucella abortus WO1993016728A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP93907031A EP0627935A4 (en) 1992-02-25 1993-02-25 Improved vaccin against brucella abortus.
BR9305970A BR9305970A (en) 1992-02-25 1993-02-25 Enhanced vaccine against brucella abortus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84161692A 1992-02-25 1992-02-25
US07/841,616 1992-02-25

Publications (1)

Publication Number Publication Date
WO1993016728A1 true WO1993016728A1 (en) 1993-09-02

Family

ID=25285312

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/001681 WO1993016728A1 (en) 1992-02-25 1993-02-25 Improved vaccin against brucella abortus

Country Status (4)

Country Link
EP (1) EP0627935A4 (en)
AU (1) AU3777893A (en)
BR (1) BR9305970A (en)
WO (1) WO1993016728A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951987A (en) * 1995-08-22 1999-09-14 Her Majesty The Queen As Represented By The Minister Of National Defence Of Her Majesty'canadian Government Polysaccharide vaccine to enhance immunity against brucellosis
ES2140336A1 (en) * 1998-01-13 2000-02-16 Inst Cientifico Tecnol Navarra Non-virulent mutants of Brucella abortus.
EP1108433A2 (en) * 1999-12-15 2001-06-20 The Minister Of National Defence Of Her Majesty's Canadian Government Combination vaccine for enhancing immunity against brucellosis
WO2003009868A1 (en) * 2001-07-26 2003-02-06 Otago Innovation Limited Antigenic compositions
AU2008202282B2 (en) * 2001-07-26 2009-07-23 Agresearch Limited Immunogenic Compositions
WO2011033129A1 (en) * 2009-09-21 2011-03-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Modified gram-negative bacteria for use as vaccines
WO2012131128A1 (en) * 2011-03-25 2012-10-04 Universidad De Navarra Diva method for differentiating animals vaccinated against brucellosis
KR20200044544A (en) * 2018-10-19 2020-04-29 대한민국(관리부서 질병관리본부장) Brucellosis diagnostic detection kit using rapid immunochromatography, its specific antibody and antibody-producing cell lines
CN116751804A (en) * 2023-05-08 2023-09-15 石河子大学 Application of VdCreA gene in growth, pathogenicity and carbon metabolism inhibition of verticillium dahliae
CN116751804B (en) * 2023-05-08 2024-05-17 石河子大学 Application of VdCreA gene in verticillium dahliae growth, pathogenicity and carbon metabolism inhibition

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2523392C1 (en) * 2013-06-07 2014-07-20 Федеральное государственное учреждение "Федеральный центр токсикологической, радиационной и биологической безопасности" (ФГБУ "ФЦТРБ-ВНИВИ") Method of emergency prevention and treatment of brucellosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1352125A (en) * 1970-07-16 1974-05-08 Wellcome Found Antigenic extracts
US4711850A (en) * 1986-01-28 1987-12-08 Novagene, Inc. Pseudorabies virus mutants, vaccines containing same, methods for the production of same and methods for the use of same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2227936B (en) * 1987-03-30 1991-09-25 Texas A & M Univ Sys Vaccine against brucella abortus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1352125A (en) * 1970-07-16 1974-05-08 Wellcome Found Antigenic extracts
US4711850A (en) * 1986-01-28 1987-12-08 Novagene, Inc. Pseudorabies virus mutants, vaccines containing same, methods for the production of same and methods for the use of same

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
Annals of Microbiology, Volume 131 A, issued 1980, N. BOSSCRAY et al.: "Antagonism Between Two Immunogens Extracted From Brucella (Cell Wall Peptidoglycan and Lipopolysaccharide Fractions) And Inactivity Of the Brucellin Allergen in Immunization of the Mouse", pages 157-169, see entire document. *
DNA, Volume 5, Number 1, issued February 1986, T.A. FICHT et al.: "Cloning the Genes Encoding the Major Outer Membrane Protein Omp III of Brucella abortus Vaccine and Virulent Strains", page 92, see Abstract. *
Infection and Immunity, Volume 42, Number 3, issued December 1983, A.J. WINTER et al.: "Immune Response to Porin in Cattle Immunized with Whole Cell, Outer Membrane, and Outer Membrane Protein Antigens of Brucella abortus Combined with Trehalose Dimycolate and Muramyl Dipeptide Adjuvants", pages 1159-1167, see entire *
Infection and Immunity, Volume 55, Number 11, issued November 1987, L.D. SMITH et al.: "Transposon Tn5 Mutagenesis of Brucella abortus", pages 2774-2776, see entire document. *
L.G. ADAMS: "Advances in Brucellosis Research", published 1990, see pages 250-276. *
Microbial Pathogenesis, Volume 11, issued December 1991, F. SANGARI et al.: "Mutagenesis of Brucella abortus: Comparative Efficiency of Three Transposon Delivery Systems", pages 443-446, see entire document. *
See also references of EP0627935A4 *
Veterinary Immunology and Immunopathology, Volume 25, issued 1990, R. SMITH et al.: "Immunogenicity of Subcellular Fractions of Brucella abortus: Measurement by in Vitro Lymphocyte Proliferative Responses", pages 83-97, see entire document. *
Veterinary Immunology and Immunopathology, Volume 26, issued 1990, R. SMITH et al.: "Induction of Lymphocyte Responsiveness by the Outer Membrane-Peptidoglycan Complex of Rough Strains of Brucella abortus", pages 31-48, see entire document. *
Veterinary Immunology and Immunopathology, Volume 26, issued 1990, R.E. PRICE et al.: "Survival of Smooth, Rough and Transposon Mutant Strains of Brucella abortus in Bovine Mammary Macrophages", pages 353-365, see entire document. *
Veterinary Immunology and Immunopathology, Volume 9, issued 1985, C.L. BALDWIN et al.: "Immune Response to Cattle to Brucella abortus Outer Membrane Proteins Measured by Lymphocyte Blastogenesis", pages 383-396, see entire document. *
Veterinary Microbiology, Volume 27, issued 1991, B.A. SOWA et al.: "SDS-soluble and Peptidoglycan-bound Proteins in the Outer Membrane-peptidoglycan Complex of Brucella abortus", pages 351-369, see entire document. *
Veterinary Microbiology, Volume 28, issued 1991, G.G. SCHURIG et al.: "Biological Properties of RB51; a Stable Rough Mutant Strain of Brucella abortus", pages 171-188, see entire document. *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951987A (en) * 1995-08-22 1999-09-14 Her Majesty The Queen As Represented By The Minister Of National Defence Of Her Majesty'canadian Government Polysaccharide vaccine to enhance immunity against brucellosis
ES2140336A1 (en) * 1998-01-13 2000-02-16 Inst Cientifico Tecnol Navarra Non-virulent mutants of Brucella abortus.
EP1108433A2 (en) * 1999-12-15 2001-06-20 The Minister Of National Defence Of Her Majesty's Canadian Government Combination vaccine for enhancing immunity against brucellosis
EP1108433A3 (en) * 1999-12-15 2003-06-25 The Minister Of National Defence Of Her Majesty's Canadian Government Combination vaccine for enhancing immunity against brucellosis
CN102294023A (en) * 2001-07-26 2011-12-28 奥塔戈创新公司 Antigenic compositions
WO2003009868A1 (en) * 2001-07-26 2003-02-06 Otago Innovation Limited Antigenic compositions
AU2008202282B2 (en) * 2001-07-26 2009-07-23 Agresearch Limited Immunogenic Compositions
AU2008202282B8 (en) * 2001-07-26 2009-08-13 Agresearch Limited Immunogenic Compositions
US7758869B2 (en) 2001-07-26 2010-07-20 Immune Solutions Limited Immunogenic compositions
WO2011033129A1 (en) * 2009-09-21 2011-03-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Modified gram-negative bacteria for use as vaccines
US8778655B2 (en) 2009-09-21 2014-07-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Modified gram-negative bacteria for use as vaccines
US9034630B2 (en) 2009-09-21 2015-05-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Modified gram-negative bacteria for use as vaccines
WO2012131128A1 (en) * 2011-03-25 2012-10-04 Universidad De Navarra Diva method for differentiating animals vaccinated against brucellosis
ES2389066A1 (en) * 2011-03-25 2012-10-23 Instituto Científico Y Tecnológico De Navarra S.A. Diva method for differentiating animals vaccinated against brucellosis
KR20200044544A (en) * 2018-10-19 2020-04-29 대한민국(관리부서 질병관리본부장) Brucellosis diagnostic detection kit using rapid immunochromatography, its specific antibody and antibody-producing cell lines
KR102124259B1 (en) 2018-10-19 2020-06-26 대한민국(관리부서 질병관리본부장) Brucellosis diagnostic detection kit using rapid immunochromatography, its specific antibody and antibody-producing cell lines
CN116751804A (en) * 2023-05-08 2023-09-15 石河子大学 Application of VdCreA gene in growth, pathogenicity and carbon metabolism inhibition of verticillium dahliae
CN116751804B (en) * 2023-05-08 2024-05-17 石河子大学 Application of VdCreA gene in verticillium dahliae growth, pathogenicity and carbon metabolism inhibition

Also Published As

Publication number Publication date
EP0627935A1 (en) 1994-12-14
AU3777893A (en) 1993-09-13
BR9305970A (en) 1997-10-21
EP0627935A4 (en) 1996-03-06

Similar Documents

Publication Publication Date Title
EP0550477B1 (en) Inactivated mycoplasma hyopneumoniae bacterin and method of use thereof
RU2194752C2 (en) Strain and culture of strain streptococcus equi tw 928 for horse vaccination
CA2758733C (en) Vaccines comprising attenuated mycoplasma bovis strains and method for the attenuation
JP2004536106A (en) Mycoplasma bovis vaccine and method for reducing pneumonia in animals
de Bagüés et al. The Brucella abortus RB51 vaccine does not confer protection against Brucella ovis in rams
EP0465204B1 (en) Vaccine against Lyme disease
US6585981B1 (en) Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
US5688682A (en) Method for producing a bacterial vaccine and novel vaccines produced thereby
US20060251674A1 (en) Formulations and process for production of Bordetella bronchiseptica P68 antigen and vaccines
WO1993016728A1 (en) Improved vaccin against brucella abortus
JP2004337175A (en) Avirulent microbes and uses therefor: salmonella
US5855894A (en) Pasteurella haemolytica type A-1 bacterin-toxoid vaccine
US5718903A (en) Vaccine comprising Brucella abortus which has O polysaccharide antigen absent
EP0757556B1 (en) Borrelia burgdorferi bacterin
WO2016005390A1 (en) Modified bacteria for improved vaccines against brucellosis
Chima et al. Immunoprophylaxis of experimental Mycoplasma bovis arthritis in calves. Protective efficacy of live organisms and formalinized vaccines
EP0636030B1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
US6019981A (en) Modified live Edwardsiella ictaluri against enteric septicemia in channel catfish
DeBey et al. In vitro lymphocyte proliferative responses and gamma-interferon production as measures of cell-mediated immunity of cattle exposed to Pasteurella haemolytica.
KR101210082B1 (en) Vaccine composition for swine polyserositis and manufacturing method thereof
KR101209964B1 (en) Vaccine composition for swine polyserositis and manufacturing method thereof
EP1108433A2 (en) Combination vaccine for enhancing immunity against brucellosis
CA2347278C (en) Vaccine based on attenuated haemophilus somnus
US6770273B1 (en) Vaccine based on attenuated Haemophilus somnus
PIJOAN Patent 2417482 Summary

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1993907031

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993907031

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1993907031

Country of ref document: EP